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ABSTRACT 
Four out of five people experience low back pain sometime during their lifetime. Problems of 
the back—and to a less extent of the neck—are consistently in the top seats among the most 
burdensome diseases in the developed world. In addition to its often-debilitating pain, low 
back pain is a major contributor to health care costs and lost productivity. Health economics 
is the study of how the health care system’s scarce resources can and should be used to 
maximise health.  
The objective of this thesis is to enhance the understanding of the economic aspects of low 
back pain. The overarching research themes are two. First, are surgical interventions for low 
back pain cost-effective? Second, what is its burden in Sweden? 
The first two papers present results from analyses of a vast database assembled from a range 
of Swedish institutions covering health care consumption of all patients with low back pain in 
the Västra Götaland region during 2000–2012. The former paper shows that the national cost 
of all patients that experienced an episode of low back pain in 2011 was €739 million or €78 
per capita. Of this, 65% were due to indirect costs such as absence from work. 
The second paper draws on the dataset to create an economic model. It shows that although 
the majority of patients improve within a few months at a relatively low cost, the sheer 
number of patients experiencing back pain make the disease costly.  
Narrowing down, using results from a randomised controlled trial, the third paper shows that 
under certain assumptions, surgical treatment of degenerative disc disease is cost-effective 
when compared to multidisciplinary treatment involving physical therapy and cognitive 
behavioural therapy. The results are not robust to different assumptions and the interpretation 
of the results should take that into account.  
The fourth and last paper also uses results from a randomised controlled trial of 
decompression surgery for spinal stenosis. This type of surgery, the most common of all 
spinal surgeries, involves treating the spinal stenosis—painful narrowing of the spinal 
canal—with decompression, where parts of bone and soft tissue are removed to make room 
for the nerves. The study shows with robust results that fusing vertebra together as part of 
decompression surgery increases costs with neither short-term nor long-term benefits.  
This dissertation shows that the burden of low back pain, including lumbar spinal stenosis 
and lumbar disc herniation, is not only heavy but distributed widely within and outside of the 
health care system. Although most treatments are effective, this thesis shows an example of 
treatments that are being used extensively but are in fact quite wasteful. This could not have 
been shown without careful research and robust methodology. In order to improve the use of 
money within the health care, research needs to be conducted to assess where to spend it.  
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1 INTRODUCTION 
Health economics is the study of allocation of scarce resources. Moreover, it possesses a 
toolbox for how these resources can be used to maximise health or other desired outcomes.  
Low back pain (LBP) is one of the most burdensome diseases in the developed world [1]. Its 
causes are wide-ranging and involve both the soft and hard tissues of the back. Diagnostics are 
difficult and error-prone. Treatments are similarly wide-ranging, from mild analgesics through 
cognitive therapy, physical therapy and surgery. The effectiveness of treatments varies and is 
often contested. Although improvements have been made in the last decades, treatment options 
and diagnostic procedures have not been shown to be universally effective [2].  
The objective of this thesis is to enhance the understanding of the economic aspects of LBP. 
The research themes are two: What is the burden of LBP in Sweden, and what can be said about 
the cost-effectiveness of treatment, in particular surgical treatments. 
6 
2 BACKGROUND 
2.1 LOW BACK PAIN 
Pain and symptoms of the back and neck are currently the biggest burden of Western societies 
in terms of years lived with disability, according to studies commissioned by the World Health 
Organisation [3]. Low back pain (LBP) specifically has been estimated to affect 80–85% of the 
world’s population at some point during a lifetime [4].  
Prevalence of chronic LBP is rising [5]. LBP has a wide range of causes and correspondingly, 
treatments and outcomes wary widely. Not less important, accurate diagnosis is difficult, 
leading to the same conditions getting different diagnoses and subsequently different treatment. 
In addition to strictly referring to pain confined to the lower spine, the term LBP is also used to 
refer to pain and problems in the legs when these can be traced to the lower back. Symptoms 
often resolve within 3 months by itself, or for example after physical therapy and other non-
surgical regimens. 
However, for a proportion of patients, the condition becomes chronic (defined as pain limiting 
usual activities for at least 3 months). If symptoms persist, patients may be referred to 
orthopaedic or neurosurgical specialists, evaluating whether surgery is indicated [6]. 
The number of surgical treatments have increased dramatically, especially in the US, where the 
number of spinal fusions per year has increased by 55% during the last decade [7]. Although a 
relatively low proportion of patients need to undergo surgery, the high number of LBP cases 
make the total number of surgeries high.  
This makes direct costs, such as to diagnosis, physical therapy, surgeries and medications high. 
Nevertheless, studies have shown that the direct costs are dwarfed by indirect costs, such as 
absence from work. In developed countries, these constitute 70–90% of the total economic cost 
related to LBP [8–10].  
This thesis investigates detail on the treatment of two specific conditions. The former is whether 
to treat degenerative disc disease surgically or non-surgically. The latter is whether adding 
fusion to a decompression surgery for lumbar spinal stenosis is warranted. These are described 
shortly in turn. 
Degenerative disc disease (DDD) refers to the degeneration of the spinal motion segment. Disc 
degeneration is associated with aging and is commonly asymptomatic. When symptomatic, 
however, it can cause significant and debilitating pain [11]. Non-surgical treatment is the 
preferred first-line treatment, including activity modification, pain medications, and physical 
therapy. When non-operative management fails, and the origin of the pain can be established, 
surgical fusion to eliminate painful motion can be indicated [11]. In recent years, total disc 
replacement (TDR) has been introduced as an alternative to fusion in selected patients [12]. 
Mean age in surgically treated DDD-patients is around 45 years. 
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Lumbar spinal stenosis in contrast is caused by a gradual narrowing of the spinal canal. Patients 
with lumbar spinal stenosis, a degenerative disorder affecting elderly with a mean age around 
70 years, typically have both pain in their lower back and legs when walking. This condition 
severely restricts function, walking ability, and quality of life. Of all indications for spinal 
surgery, lumbar spinal stenosis has become the most common [13], explained by an aging 
population.  
2.2 HEALTH ECONOMICS 
Economics are commonly defined as the study of scarce resources. Health economics, by 
extension, is the study of allocation of scarce resources wherever health or healthcare are 
involved, usually focused on costs (inputs) and the consequences (outcomes) of health care 
interventions. As it incorporates elements from medicine and pharmacology, among other 
fields, it is not considered just as a branch of economics, but rather a related multidisciplinary 
field [14]. 
With progress in pharmacology and medicine in general, ever more treatment options are 
available, competing for the finite resources allocated to health care. In light of this, physicians 
and other decision-makers turn to health economics as scientific and sound economic 
evaluations of health-care interventions are critical for decision-making in health care if the goal 
is to optimize the life and health obtained with given resources. 
Health-economic evaluations can be valuable when deciding whether the gains following a 
specific treatment, both in terms of health in savings within the health-care system or society at 
large, can be justified. Costs can in this sense be seen as not the money per se that an 
intervention requires, but rather the foregone use of the same money, whether within or outside 
the health-care system. The onus is on the healthcare system and health economists to make 
sure the available money is put to the optimal use.  
Seen in relation to the incidence and high economic impact of LBP, economic evaluations of 
different interventions are scarce. Surgery may be considered as expensive. Patients and their 
relatives may lose many days of work, and the costs of rehabilitation can be considerable. The 
main tools and concepts of health economics as used in this thesis are presented in turn.  
2.2.1 Quality of life and quality-adjusted life years 
When allocating resources across the whole health care system, consequences of the spending 
can be wide-ranging. Longer life provided by one treatment might need to be compared with 
less pain by another, less anxiety or lower risk of an uncertain outcome. To overcome the 
heterogeneity of this, a one-dimensional instrument was needed to assess quality of life (QoL). 
By multiplying QoL by the time in which a person spends in a given state, a measure of quality-
adjusted life years (QALYs) can be calculated. Using this measure, treatments with disparaging 
outcomes can be compared on a shared metric.  
8 
To assess QoL, several metrics have been developed. EQ-5D is the most commonly-used one 
available. It is a generic measure of utility that generates an index-based summary score based 
on societal preference weights. It includes measures of health status across five dimensions: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, from which a 
utility index score is computed that can range from less than 0 (worse than dead) to 1 (perfect 
health). 
SF-6D and SF-36 are other instruments with similar purpose. Although there are doubts about 
the interchangeability of the two instruments, they are often used either together or separately 
[15].  
2.2.2 Costs 
Costs in health economic analyses are commonly divided into two or three categories.  
First, direct costs are costs of hospital visits, outpatient care, procedures, diagnostics, devices 
and other services. Non-medical related costs are also often included, such as transportation 
costs and social assistance. 
Indirect costs are costs that usually are not paid directly but arise nonetheless. These are chiefly 
productivity loss due to the illness, such as the foregone production because of absence from 
work or early retirement.  
The third category sometimes included, is the valuation of non-monetary effects of illness or its 
treatment. Mainly, this refers to calculations where QALYs are assigned monetary value. 
The perspective of the study is an important factor in the design and interpretation. Some have a 
societal perspective, where all costs are counted regardless of where they accrue, while other 
have a health care perspective, where only costs related to the health care system are measured. 
The latter would exclude indirect and intangible costs [16]. 
2.2.3 Cost-effectiveness 
Cost-effectiveness refers to the relationship between costs and effectiveness. In health economic 
analyses, effectiveness is measured with QALYs. When two mutually exclusive treatments are 
compared, the difference in costs is divided by the difference in QALYs. The result is called the 
incremental cost-effectiveness ratio (ICER). An ICER can be interpreted as being the price at 
which QALYs can be created. Whether an ICER is high or low depends on the decision-
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maker’s willingness to pay (WTP) for a QALY. The ICER from such calculations can be 
plotted on a cost-effectiveness plane.  
Figure 1: Cost-effectiveness plane. The plane shows the difference between two treatments being compared, where 
one of the treatments—the control—is at the intersection between the two lines with coordinates [0,0]. If the other 
treatment is cheaper and creates more QALYs, it falls into quadrant 2. Such treatments are said to be dominating 
as they should be adopted immediately. Treatments that are more expensive and create net loss of QALYs fall into 
quadrant 3. These are said to be dominated and should be avoided. A line in Q1 shows the trajectory of the 
willingness to pay (WTP). Treatments that fall into Q1a are below the line and thus provide adequate value for 
money, while treatments above the line are too expensive to be adopted at the given WTP. Treatments falling into 
quadrant 3 are difficult to interpret, as it involves decreasing the service provided to save money.  
Cost-effectiveness studies of treatment of LBP are presented in chapter 2.4. 
2.2.4 Burden and cost of illness 
Cost of illness (COI) is a type of study intended to measure the economic burden of disease on 
the whole population. Usually, COI include direct costs and indirect costs as measured in loss in 
productivity related to the illness in question. Also, COI can comprise non-economic factors 
such as loss in QALYs, where the loss in QALYs are translated into monetary values.  
Studies of this kind are both conducted on specific diseases and on whole disease burden on 
societies. This can be exemplified in the Global Burden of Disease project which both includes 
holistic view on disease burden [17] and dives into specifics of for example LBP[4].  
COI studies can be used to draw attention to particular health problems and encourage policy 
debate, and also to inform planning of healthcare services, the prioritization of prevention 
research and the evaluation of policy options [18]. Such studies give no direct guidance of how 
resources should be allocated to improve efficiency. However, they can give information about 
the total societal burden which can be important when determining what attention and 
awareness the disease should be given in, for example, public health interventions.  
Also, COI studies can map who and to what extent different stakeholders bear the burden of 
disease—be it the healthcare sector, the patients or the employers. As such, COI studies can be 
the building block on which both academia and the health care sector can build to improve 
decision making.  
ΔCost 
ΔQALY 
     Q1b    
Q4      Q1a 
Q3  Q2 
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For details on the burden of LBP in particular, see chapter 2.5, Economic burden.  
2.2.5 Modelling in health economics 
Health economic models are mathematical frameworks that relate the course of the illness to the 
use of the alternative interventions and other factors. By using such a model, the often-limited 
clinical trial data can be extrapolated to longer periods of time, other populations and different 
practices than those studied in the trial. Also, expected costs and impact on QoL can be added. 
The models also allow for the quantification of uncertainty around estimates [19].  
The simplest form of models are decision trees, where two or more possible outcomes or 
choices are compared. These can be made more elaborate by adding branches to the tree, adding 
probabilities and thus make possible the calculation of expected values. However, this 
framework quickly becomes too simplistic, especially when looking at long time horizons and 
many different outcomes.  
The usual answer to the shortcomings of decision trees is to construct Markov cohort models. 
These take a time horizon, from a few months up to years or decades, and divide these into 
discrete cycles. Possible outcomes are grouped into states, each assigned an outcome of QoL 
and cost. Transition probabilities are used to transfer the starting cohort between states at the 
end of each cycle. By summing up QALYs and costs over all states and cycles, different 
treatments can be assessed.  
Markov cohort models have long since become a standard in the health economist’s toolbox, in 
part due to their versatility and ease of extensions. However, depending on the treatment and 
disease progression, even these can become too simplistic. Particularly, if the number of states 
becomes too high or if states, cycles and transition probabilities need to be dynamic. In 
particular, when patient history needs to be taken into account, individual-level microsimulation 
methods are often required [19, 20].  
Patient-level simulations come in many forms, some adapting methods from engineering and 
production optimisation. These can either be in continuous time or discrete time, the former 
usually take the form of discrete event simulations. The latter can in some ways be similar to 
Markov cohort models, except integrating patient history and only following one patient 
through the model each time, and then repeating the exercise thousands of times. An individual 
state model was used in paper II.  
2.3 RANDOMISATION AND REAL-WORLD DATA 
As this thesis consists both of results from randomised studies and real-world data, their relative 
strengths and weaknesses should be discussed.  
Randomised controlled trials (RCTs) are regarded as the gold standard in medical research. The 
randomisation—in conjunction with blinding and other methods—is intended to ensure that no 
confounders or bias are present and that effects can be assigned to their respective treatment 
rather than circumstances or chance.  
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However, RCTs, particularly for surgical interventions, have their drawbacks. First, they derive 
data from often tightly controlled environments, where stringent inclusion and exclusion criteria 
are used to select a patient population that may be a biased sample of the whole population. 
Second, they create an artificial environment that does not always represent real-world 
practices. Third, contrary to placebos in pharmacological studies, it is problematic to conduct 
placebo-surgeries (often referred to as sham procedures), both for ethical reasons, but also 
because of the difficulty of designing a procedure that masks for the patient which group he/she 
was randomized into, but at the same time does not constitute a treatment. 
RCTs are in general—and quite importantly for health-economic evaluations—often limited in 
time and of a limited scope. This is a problem as all relevant costs and effects should be 
captured by such an evaluation, wherever and whenever they incur, as long as they are relevant 
to the treatment under consideration. Survival benefits in the future or long-lasting effects of a 
particular treatment regimen are thus not captured in for example a 2-year long study, skewing 
cost-effectiveness from expensive and long-lasting treatments to cheap ones with short-term 
effects. 
These reasons, along with high costs of conducting RCTs, have contributed to a rise in interest 
in real-world data (RWD). By combining registers, both medical registers and various 
government data, real-world data can answer questions where RCTs are not feasible. Also, such 
studies can be used to validate results from RCTs. Studies that have compared RCT-derived 
data to RWD have shown that the two approaches can give comparable results if data is used in 
a scientifically sound manner [21]. 
2.3.1 Analysing crossover and drop-outs 
When analysing results from RCTs, specific statistical problems arise when the study protocol 
is not followed. Of these, two problems and their solution will be mentioned here.  
First there is the crossover. In the context of RCTs with treatments A and B, crossover is when 
patient assigned to treatment A does not receive the treatment, either receiving treatment B, a 
different treatment or none at all. This can have profound effect on the results, the most famous 
example within LBP probably being the SPORT trial where 50% of patients assigned to surgery 
received surgery within 3 months of enrolment, while 30% of those assigned to nonoperative 
treatment received surgery in the same period [22]. 
The way to analyse such cases is to use intention to treat analysis (ITT). This dictates that 
patients should be analysed using their assigned group. The other approach, per protocol (PP), 
is to analyse according to treatment received.  
Arguably, patients who do not follow their randomized treatment are in one way or another 
different from the rest of their treatment group. Some of these differences can be observed. 
However, unobserved differences cannot be ruled out; indeed, it is quite likely that patient 
characteristics dictate whether they follow protocol or not. For this reason, ITT analysis is 
considered the gold standard in health economic evaluations [23].  
12 
Additionally, questions in health economics often are about what policy health authorities 
should adopt and which should be rejected. In this sense, the question is not whether a surgery 
works, but whether the decision to operate surgically is a good policy or not, regardless of 
whether the patients receive the operation or not. This view has parallels in studies of self-
administered drugs. There, the interesting question from a health economic perspective is 
whether prescription of drug is cost-effective rather than the narrower use of drugs.  
2.4 COST EFFECTIVENESS 
In a literature review, detailed in chapter 4.2, 57 articles were identified. Of these, 11 considered 
cognitive behavioural therapy or other psychological treatments, four pharmacological 
treatments, 14 surgical treatments, 14 physiotherapeutic treatments, 23 other non-surgical 
interventions and six alternative medicine. The vast majority described treatments to non-
specific LBP or 52, while three mentioned stenosis, two disc herniation, four degenerative disc 
disease and seven other specific conditions (some looked at more than one diagnoses, hence the 
sum higher than 57). Papers commonly looked at more than one form of treatment and/or more 
than one form of conditions, so the sum is higher than the number of papers. 
The results of Andronis et al. [24], who also systematically reviewed evidence on cost-
effectiveness of non-surgical treatments were that “combined physical and psychological 
treatments, medical yoga, information and education programmes, spinal manipulation and 
acupuncture are likely to be cost-effective options for LBP.“ The cost-effectiveness of physical 
exercise programs are less certain.  
No simple messages can be extracted from the review. This stems from the difficulty of 
diagnostics, the complex nature of the underlying ailments and methodological hurdles among 
other things. The relative lack of literature in the field, given the immense burden, is however a 
matter of concern.  
2.5 ECONOMIC BURDEN 
Pain in back and neck is the fourth most burdensome disease category, as measured with 
disability-adjusted life years (DALYs). In the developed world, where communicable diseases 
have largely been eliminated, spinal ailments top the lists in most countries [17]. Indeed, out of 
all 291 conditions studied in the global burden of disease study, LBP was the most burdensome 
in terms of disability and sixth in terms of overall burden [4]. The difference between the two 
measures was that the former measured disability in living people, while the latter the burden 
both in disability and lost life years. LBP is not in itself a cause of premature mortality, thus the 
resulting difference. In Sweden, the number of disability adjusted life years lost per capita 
increased by 0.065% annually over the last 25 years, according to the same study [17]. 
Importantly, however, these numbers do not consider costs, neither direct nor indirect. 
LBP was the largest diagnosis group in all paid short term sick leave benefits in Sweden in 2001 
[25]. LBP is very common, and at any given point in time, 15–30% of the population suffers 
13 
 
 
from the disorder while 60–80% of the population has at some point in life suffered from the 
condition [26–28] Despite its considerable contribution to disability worldwide, the attention 
LBP has received has delivered less than optimal improvement for those affected on a group 
level.  
In addition to direct treatment costs, indirect costs, such as productivity loss and costs 
associated with care provided by relatives stack up to a high aggregated cost. Using a top-down 
approach the burden of LBP in Sweden has been estimated at €1,860 million in 2001 prices, 
where indirect costs accounted for 84% of total cost [8]. As a comparison, in 2014 prices, 
burden per capita per year has been estimated to approximately €410 in Europe [29] and €317 
in Australia [30]. 
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3 AIMS OF THE THESIS 
3.1 GENERAL AIMS 
The objective of this thesis is to enhance the understanding of the economic aspects of low back 
pain (LBP), including lumbar disc herniation (LDH) and lumbar spinal stenosis (LSS).  
The overarching research themes are two: 
• What is the burden of LBP in Sweden?  
• Are surgical interventions for LBP cost-effective?  
3.2 SPECIFIC AIMS 
However, these questions are very broad and cannot be fully answered in a single thesis, in 
particular the second one. Thus, these two questions are answered with two papers each with 
narrower scope and aims. 
3.2.1 Cost of low back pain (paper I) 
To estimate the societal costs of low back pain with or without radiating leg pain. 
3.2.2 Treatment pathway model (paper II) 
To develop a health economic model to evaluate the long-term costs and outcomes over the 
healthcare treatment pathway for patients with LBP. 
3.2.3 Cost-effectiveness of total disc replacement in patients with chronic low 
back pain (paper III) 
To evaluate the cost-effectiveness of total disc replacement (TDR) versus multidisciplinary 
rehabilitation (MDR) in patients with chronic LBP. 
3.2.4 Cost-effectiveness of fusion in decompression surgery for lumbar spinal 
stenosis (paper IV) 
Determine whether decompression plus fusion (DF) is cost effective compared with 
decompression alone (D) in lumbar spinal stenosis, with or without degenerative 
spondylolisthesis.  
15 
 
 
4 REVIEW OF LITERATURE 
The thesis is comprised of four sub-studies, all tied together with the common thread of the title, 
health economic aspects of low back pain and lumbar spinal stenosis.  
Each study, however, covers a specific aspect of this broad theme and contributes in different 
ways to the research frontier. The literature review is thus structured in two parts; recent 
research in assessment of the burden of LBP and LSS and the cost-effectiveness of 
interventions. 
4.1 BURDEN OF LOW BACK PAIN 
A systematic literature search was made to identify literature studying burden of low back pain. 
The search was confined to research published in the last 15 years in English, and as MeSH 
terms were used, was confined to Medline/Pubmed. The search identified articles about the 
economic aspects of low back pain, adding the constraint of including the word burden1. 
Studies that focused on a single or a subset of treatments or diagnoses were excluded in title and 
full text review. Only papers in English were included.  
A PRISMA flowchart is presented below with an overview of the identified literature.  
The identified literature was divided into three categories; global assessments of burden, 
systematic reviews, and regional and local assessments, as detailed in Table 1.  
 
                                                 
1 "Low back pain/economics"[mesh] "last 15 years"[dp] burden eng[la] 
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Figure 2: PRISMA flow chart of literature review of burden 
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4.1.1 Global assessments of low back pain 
According to the global burden of disease-project, pain in back and neck is the fourth most 
burdensome disease category, as measured with disability-adjusted life years (DALYs). In 
the industrialised world, where big strides forward have been made in treating communicable 
diseases and heart diseases, spinal ailments top the lists in most countries [17].  
Indeed, out of all 291 conditions studied in the global burden of disease study, LBP was the 
most burdensome in terms of disability and sixth in terms of overall burden [4]. The 
difference between the two measures was that the former measured disability in living 
people, while the latter the burden both in disability and lost life years. LBP is not in itself a 
cause of premature mortality, thus the resulting difference.  
For number of years lived with disability, LBP ranked first place in almost all regions, going 
lowest to fourth place in the Caribbean and Southern sub-Saharan Africa. In lost disability-
adjusted life-years, it ranked lowest 23rd in Central sub-Saharan Africa, but up to first place in 
both Western Europe and Australasia [4]. The global point prevalence of LBP was estimated 
to be 9,4%, effectively meaning that in any given year, 9,4% of the world population has 
LBP. The definition specifies that the pain must be “activity-limiting LBP (with or without 
pain in lower limbs) that lasts for at least one day”. 
Although thorough, the global burden of disease studies involved a range of guesswork, both 
generally and for LBP specifically. Its main conclusion, however, is that by using 
standardised measures and by looking globally, the real burden can be assessed. 
Subsequently, research and clinical priorities can be adjusted, and although no formal 
assessment has been found, there does seem to be a lack of research on LBP seen in relation 
to its burden. Subsequently, Hoy et al.[4]—repeating a pattern common in other literature on 
the subject—claim that there is an “urgent need for further research to better understand LBP 
across different settings.” 
This lack of research can be seen in the epidemiological literature, where estimates of one-
year incidence range from 1.5–36% and recurrence at 1 year range from 24–80%. These wide 
ranges can in big part be attributed to differences in definitions [26]. 
4.1.2 Reviews 
Dagenais et al. [31] published in 2008 another systematic review of cost of illness studies 
from 1997 to 2007. Stating wide differences in methodology, it showed that by any measure, 
the burden was considerable. The study found total 27 relevant studies with cost per capita 
ranging from less than a dollar (48 JPY in 1994) to 500 today’s dollars (474 AUD in 2001). 
The authors found the lack of a study of LBP’s total societal burden in the USA to be 
especially glaring, potentially yielding a sub-optimal devotion of resources aimed at the field. 
Among the conclusions was that lowering indirect costs may be the best opportunity to lower 
the costs of LBP.  
  
Disparaging methodologies between studies was one of the main conclusions of a paper by 
Hoy et al. [32]. However, at this point, a set of recommendations put forth in a Delphi study 
from 2008 [33], in particular how prevalence studies should define LBP. This paper focused 
on the only on the prevalence of LBP would later become a part of the global burden of 
disease mentioned above. It included both a more global search for publication, an attempt to 
assess risk of bias and more specific definitions than previous reviews. A multivariate 
analysis showed that prevalence was higher among females than males, similar between 
urban and rural populations, and almost two times higher in high income countries as 
compared to low income countries.  
Juniper et al. [34] studied the epidemiology, economic burden and pharmacological treatment 
of chronic LBP in France, Germany, Italy, Spain. In assessing the economic burden, they also 
conducted a literature review. For resource utilization, the study found four studies and for 
indirect cost estimates three studies, one for Germany, Spain and the UK each. All studies 
were small, methodologically limited and by now outdated. 
4.1.3 Regional and local assessments 
4.1.3.1 Sweden 
Two studies from the same research group were identified that present burden estimates for 
Sweden. One focused solely on costs and used a top-down approach [8], while the other used 
survey data and bottom-up approach [9], with the latter including also a measure of quality of 
life. The bottom-up approach suffers from low response frequency (9%) of patients recruited 
at outpatient care facilities in Sweden. The average annual cost of chronic LBP per patient 
was estimated at €20,700, of which 85% were indirect costs. Based on this, the authors found 
it particularly important to find treatments that reduce the high costs of sick leave and early 
retirements because of chronic LBP. 
The top-down approach included inpatient and outpatient care, prescriptions and indirect 
costs, both short-term and long-term. Again, indirect costs accounted for 84% of the total 
burden. Intangible costs (cost of lost quality-adjusted life-years) were also calculated, with 
the authors finding the total cost to be five times higher. Intangible costs are usually not 
included in base case analyses of such research but can be instructive in assessing the value of 
eradicating a disease.  
4.1.3.2 Other European countries 
Using data from the United Kingdom General Practice Research Database, Hong et al. [35] 
calculated costs associated with the treatment of chronic LBP. Given the available data, the 
study only looked at direct costs, comparing chronic LBP patients with a matched control 
group. Of the cost difference amounting to £500, 60% was for consultation by general 
practitioners, 22% by secondary care and the rest due to pharmaceuticals.  
20 
Depont et al.[36] published in 2009 a retrospective, observational, cohort study in primary 
care in France. The study included around 800 adult patients with chronic LBP between 
October 2001 and December 2002. The total mean cost per patient over six months was 
slightly more than €700. Of these, 23% were by physiotherapists and similar specialists, 20% 
to medications, 17% to hospitalizations, 10% to diagnostics and 13% to physician fees. No 
attempt was made to collect indirect costs.  
Wieser et al. [37] studied LBP in Switzerland in 2005. It was a bottom-up prevalence-based 
cost-of-illness study with a societal perspective. The data used was a questionnaire completed 
by a sample of 2,500 around half suffered from LBP in the last 4 weeks and 350 of them were 
receiving medical treatment for their LBP. Direct costs of LBP were estimated at €2.6 billion 
and direct medical costs at 6.1% of the total healthcare expenditure in Switzerland. 
Productivity losses were estimated at €4.1 billion with the human capital approach and €2.2 
billion with the friction cost approach. The total economic burden of LBP to Swiss society 
was between 1.6 and 2.3% of GDP.  
The study’s main addition to the literature is however its estimates of presenteeism (loss of 
productivity while at work), as being the single most prominent cost category. As for other 
data, this was collected using questionnaires, which are said to be reliable when recall periods 
are short (1 or 2 weeks), and that the link between claimed presenteeism and actual 
productivity is quite strong.  
4.1.3.3 Other  
Mehra [38] looked at US claims database for the years 2006–8, having records for 40 
thousand patients, comparing patients with and without neuropathic pain. Of the sample, 90% 
had neuropathic pain. Mean annual cost of care per patient was 160% higher for patients with 
neuropathic pain than without (US$ 2577 and US$1007 respectively). 
This difference between the two groups lead the authors to claim a “greater need for new 
treatment options that more comprehensively manage the range of pain symptoms and 
signalling mechanisms involved”. 
Wasiak et al. [39] studied workers’ compensation claims data for low back injuries in a New 
Hampshire, USA. The results, based on claims on 1900 workers, indicated that 17% had 
recurrent work disability and 34% received recurrent care. Recurrences contributed 
disproportionately to the total burden of work-related nonspecific injuries. 
Lastly, Walker et al. [30] estimated the cost of illness in Australia. The total cost was 
calculated at $9.2 billion AUD, whereof 89% were indirect costs. The authors say the burden 
is so great “that it has compelling and urgent ramifications for health policy, planning and 
research”, where particular focus should be on indirect costs and cost-effective management 
regimes that encourage an early return to duties. 
  
4.2 COST-EFFECTIVENESS OF TREATMENT 
Given the high burden of LBP, it is essential to find treatments that are effective, and more to 
the point here, cost-effective.  
The literature search involved searching for evidence of cost-effectiveness of interventions 
for low back pain. The MeSH-term for cost-effectiveness was deliberately used so as to also 
include other similar analyses such as cost-benefit and cost-utility analyses. No specific 
diagnosis was excluded or explicitly included. To limit the size of the literature search, only 
papers from the last 15 years were included and protocols were excluded. Some measure of 
quality of life or utility was required to be included, in line with Indrakanti et al. [40]. Only 
papers in English were included. The search was limited to PubMed. Reviews were included, 
and ad-hoc inclusion of papers allowed2.  
Figure 3 shows a PRISMA-inspired flow-chart. Gross number of papers included was 94, 
with 57 included in the final qualitative review. 
 
 
  
                                                 
2 Search string: "Cost-Benefit Analysis"[Mesh] AND "Low back pain"[mesh] "last 10 years"[dp] english[la] 
NOT protocol[ti] AND ("quality-adjusted" OR "quality of life" OR QALY OR "life years" OR "EQ-5D" OR 
"SF-6D" OR "SF-36") 
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Figure 3: PRISMA flow chart of literature search for cost-effectiveness 
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4.2.1 Physiotherapy 
Tsertsvadze [41] conducted a systematic review of trial-based economic evaluations of 
manual therapy relative to other alternative interventions used for the management of 
musculoskeletal conditions. Six trials were identified for LBP. Manual therapy techniques 
(e.g., osteopathic spinal manipulation, physiotherapy manipulation and mobilization 
techniques, and chiropractic manipulation with or without other treatments) were more cost-
effective than usual general practitioner care alone or with exercise, spinal stabilization, GP 
advice, advice to remain active, or brief pain management for improving low back 
pain/disability. The authors caution however that at present there is a paucity of evidence on 
the cost-effectiveness evaluations for manual therapy interventions. Further improvements in 
the methodological conduct and reporting quality of economic evaluations of manual therapy 
are warranted in order to facilitate adequate evidence-based decisions among policy makers, 
health care practitioners, and patients.  
Hoeijenbos et al. [42] compared whether actively implementing an evidence-based 
physiotherapy guideline for non-specific low back pain to the standard method of 
dissemination. Measuring both quality of life and costs, no discernible effect was seen on 
neither costs, productivity nor utility, rendering the active implementation not cost-effective. 
Critchley et al. [43] used a pragmatic, randomized, assessor-blinded, clinical trial to compare 
the effectiveness and cost-effectiveness of three kinds of physiotherapy common in treatment 
of LBP. More than 200 patients were randomized to spinal stabilisation classes, 
physiotherapist-led pain management or usual outpatient physiotherapy.  
Although all regimens improved outcomes, the cost-effectiveness was best for the 
physiotherapist-led pain management, giving a chance for cost-reduction without threating 
patient outcomes.  
Rivero-Arias et al. [44] report from an economic evaluation alongside a pragmatic 
randomized controlled trial, conducted to compare routine physiotherapy with an assessment 
session and advice from a physiotherapist for patients with LBP. Almost 300 patients were 
enrolled. Although health care system costs were not significantly different, out-of-pocket 
expenses were, favouring the advice group. Utility levels improved similarly in both groups, 
suggesting that advice given by a physiotherapist should be considered as the first-line 
treatment for patients with LBP. 
Smeets et al. [45] examined whether a combination of a physical training and operant-
behavioural graded activity with problem solving training is cost-effective compared to either 
alone at one year after treatment. 172 patients with chronic disabling non-specific LBP, were 
randomized to a course of active physical treatment, psychological treatment or a 
combination of both. The psychological treatment turned was cost-effective, the physical 
therapy less so, while the combined therapy was not cost-effective.  
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Steenstra [46] evaluate the cost-effectiveness of a return-to-work program for workers on 
LBP-induced sick-leave. The trial randomized patients to either a workplace intervention 
implemented between 2 to 8 weeks of sick-leave with usual care, and a clinical intervention 
after 8 weeks of sick-leave with usual care. The authors summarise the findings as follows 
“the workplace intervention results in a safe and faster RTW than usual care at reasonable 
costs for workers on sick-leave for two to six weeks due to LBP.” 
Van der Roer and colleagues [47] evaluated the cost effectiveness of an intensive group 
training protocol compared with usual care physiotherapy in patients with nonspecific chronic 
LBP. The intensive group training protocol combines exercise therapy, back school, and 
behavioural principles. After 1 year, the group that received the intensive treatment had 
accrued higher direct costs the direct health care costs were similar, as were outcomes, 
yielding rather inconclusive cost-effectiveness estimates. The authors recommended however 
that the intensive group training protocol not be implemented at a national level, opting rather 
for the less-intensive version in the absence of better evidence. 
Whitehurst [48] calculated the cost effectiveness of a brief pain management program 
targeting psychosocial factors compared with physical therapy for primary care patients with 
early LBP, with 200 patients in each group. There were no statistically significant differences 
in mean health care costs or outcomes between treatments. Statistically insignificant 
differences were in favour of physical therapy on the utility side, but on the pain management 
on the cost side. The calculated incremental cost-per-QALY ratio indicated that there is only 
a 17% chance that brief pain management provides the best value for money. Physical 
therapy is a cost-effective primary care management strategy for low back pain. However, the 
absence of a clinically superior treatment program raises the possibility that a combined 
therapy could be considered.  
Fritz et al. [49] conducted a study comparing whether early physical therapy was cost-
effectiveness or not. The addition of physical therapy increased both costs and quality of life, 
with an acceptable ICER, leading the authors to claim the addition to be cost-effective for 
patients with acute, nonspecific LBP.  
Hahne et al.[50] studied whether individualized physical therapy is a better use of money than 
the traditional guideline-based advice. The study included 300 people randomly assigned to 
either two guidelines-based sessions or ten individualized. Interestingly, total costs were 
similar, but the individualized regime created significantly better results.  
Given these conclusions, the study mentioned above that looked into combined psychological 
and physical therapy did not indicate that the combination is cost-effective [45]. Likely, the 
results of such programs vary on the patient population and details of the interventions.  
Andronis et al. [24] systematically reviewed evidence on cost-effectiveness of non-surgical 
treatments and found that “combined physical and psychological treatments, medical yoga, 
information and education programmes, spinal manipulation and acupuncture are likely to be 
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cost-effective options for LBP.“ The cost-effectiveness of physical exercise programs are less 
certain.  
4.2.2 Surgical procedures 
Evaluations of surgical procedures can be divided into those comparing similar surgical 
procedures, and those comparing surgery with non-surgical management.  
4.2.2.1 Lumbar Spinal Stenosis 
Tosteson [51] reported on outcomes of surgery over 2 years among patients with stenosis 
with and without degenerative spondylolisthesis, with non-operative care as a control. 
Among 634 patients with stenosis, 62% had surgery, most often decompressive laminectomy. 
Stenosis surgeries improved health to a greater extent than nonoperative care (0.17 QALYs) 
at a cost of $77 600 per QALY gained. Degenerative spondylolisthesis surgeries significantly 
improved health versus non-operative care (QALY gain, 0.23), at a cost of $115 600 per 
QALY gained. The authors concluded that the economic value of spinal stenosis surgery at 2 
years compared favourably with many health interventions. Lastly, the authors conclude that 
surgery for degenerative spondylolisthesis surgery is “not highly cost-effective over 2 years 
but could show value over a longer time horizon”. 
As a part of the same research project, Weinstein et al. [52] reported on the cost-effectiveness 
calculations based on results from the seminal SPORT-study. At 4 years’ follow-up the ICER 
for surgery was $20,000, $59,000 and $64,000 per QALY for disc herniation, spinal stenosis 
and degenerative spondylolisthesis respectively. The first one is usually regarded as cost-
effective, while the second two are more doubtful.  
4.2.2.2 Lumbar Disc herniation 
In Hansson [53], 92 individuals in a cohort of more than a thousand Swedish subjects 
underwent lumbar disc herniation surgery, where each surgical patient was matched with a 
patient treated conservatively. Direct costs were much higher for surgical treatment with 
indirect costs being lower. The median QALYs gained were 0.363 for surgical cohort and 
0.036 for those receiving conservative care, and with low difference in total costs, Surgery for 
lumbar disc herniation was deemed cost-effective. 
4.2.2.3 Surgery and non-specific conservative treatment 
In patients with chronic LBP Johnsen et al.[54] compared surgical intervention of total disc 
replacement with multidisciplinary rehabilitation. The surgical intervention yielded higher 
QALYs (0.34), but although the surgery was more expensive up front, the cost addition was 
recuperated in lower follow-up costs, particularly indirect costs. As the quality of life was 
different at the end of the follow-up, longer study period is needed to accurately assess the 
total cost and outcomes. 
  29 
Rivero-Arias [55] inspected the cost-effectiveness of surgical stabilisation compared with a 
programme of intensive rehabilitation for the management of patients with chronic LBP by 
analysing data from an RCT. In short, the surgery was costlier, and although the outcomes 
were slightly better, the improvement was not deemed cost-effective. One aspect of the study 
was considerable crossover between treatment arms. If the proportion of rehabilitation 
patients requiring subsequent surgery continues to increase, the cost-effectiveness of the 
surgical intervention could be impacted somewhat.  
Van den Hout et al.[56] compared early surgery with prolonged conservative care in terms of 
cost-effectiveness in patients with sciatica caused by lumbar disc herniation. Surgical 
treatment was more expensive for the health care system, but savings in indirect costs negated 
the cost increase almost entirely. Surgery, leading to better clinical outcomes, should thus not 
be withheld for economic reasons.  
4.2.2.4 Surgical techniques  
Parker [57] reported on a study comparing minimally invasive lumbar fusion compared to 
open surgery for patients with degenerative disc disease. Only 15 patients were in each group 
and differences between them did not reach statistical significance.  
Lumbar artificial intervertebral disc replacement (AIDR) were compared by Parkinson et al. 
[58] with lumbar fusion for the treatment of patients suffering from LBP and or radicular pain 
who have failed conservative treatment. Five different fusion approaches were tried in this 
study, that was based on published effectiveness data synthesized in a Markov model. The 
artificial discs were found to be cost-saving compared with fusion overall ($1600/patient); 
however, anterior lumbar interbody fusion and posterolateral fusion were less costly. As a 
result, the ICER depends on the outcome considered and the comparator. The artificial discs 
are thus potentially cost-saving.  
In 2-year RCT, Christenen [59] compared the cost and utility of transforaminal lumbar 
interbody fusion to that of posterolateral instrumented fusion. The former method is a newer 
one with a prospect of lower complication rate. However, the study did not show any 
difference, neither in cost or outcomes, between the two methods. Subsequently, the authors 
conclude that transforaminal lumbar interbody fusion “does not seem to be a relevant 
alternative to PLF from a socioeconomic point of view.” 
Freeman [60] compared two techniques in lumbar fusion, titanium cages and femoral ring 
allografts. The study showed that titanium cages was not cost-effective. In fact, the allografts 
were both cheaper, better and patients returned to work quicker.  
Soegaard [61] reported on a cost-utility evaluation of an RCT with 4- and 8-year follow-ups 
of circumferential fusion versus posterolateral fusion for LBP. In short, the former method 
was shown to be dominant.  
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Fritzell et al. [62] reported on an assessment of the cost-effectiveness of total disc 
replacement when compared with instrumented lumbar fusion. Social and healthcare 
perspectives after 2 years are reported. In all, 152 patients were randomized to each group, 
and at the 2-year follow-up the result was similar in both groups. 
4.2.3 Psychological treatments including cognitive behavioural therapy 
Norton [63] conducted a CUA of CBT for the treatment of persistent non-specific LBP from 
the perspective of US commercial payers using a Markov model. The analysis revealed an 
acceptable cost for the treatment, and the results were robust across numerous sensitivity 
analyses.  
Psychosocial factors appear to be of importance in the development and prognosis of LBP. 
As reported by Jellema [47], more than 300 patients with non-specific subacute LBP were 
randomized to psychological intervention or usual care. Differences in clinical outcomes 
between both the groups were small and not statistically significant. Differences in costs were 
however in favour of the psychological intervention. However, the complete case analysis 
and the sensitivity analyses with imputed cost data were inconsistent with regard to the 
statistical significance of this difference in cost data, and as a result, the cost-effectiveness is 
uncertain. Given the uncertainty, the authors conclude that usual practice should not be 
changed.  
Johnson et al. [64] set up an RCT to study whether a group program of exercise and 
education using CBT reduces pain and disability over a subsequent 1-year. Also, the study 
was set up to estimate cost-effectiveness of the intervention. The intervention arm received a 
program of eight 2-hour group exercise session over 6 weeks comprising active exercise and 
education delivered by physiotherapists using a CBT approach. Both arms received an 
educational booklet and audio-cassette. The intervention showed only a small and 
nonsignificant effect at reducing pain and disability with low additional cost. The estimated 
ICER was £5000/QALYs. Although being cost-effective, the intervention produces only 
modest improvements in pain and disability.  
Lamb et al. published in 2010 papers [65, 66] an RCT with 700 patients where patients were 
randomised to receive active management (a non-surgical program intended to keep patients 
active), and active management plus a version of CBT. A year after randomization, 60% of 
the combined program reported some or complete recovery, compared to 31% in the control 
group. The intervention was cheap with an ICER of only £1786.  
Schweikert et al. [67] investigated return to work and cost-effectiveness of the addition of 
cognitive-behavioural treatment to standard therapy compared to standard 3-week inpatient 
rehabilitation for patients with chronic low back pain. More than 400 patients were randomly 
assigned to usual care or usual care plus cognitive behavioural treatment.  
Between groups, there were no significant differences in quality-adjusted life-years gained or 
in direct medical or nonmedical costs. The cognitive behavioural treatment showed lower 
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indirect costs. Adding a cognitive behavioural component to standard therapy may reduce 
work days lost and thus decrease indirect costs. 
Gossens et al. [68] compared exposure in vivo (EXP) to more commonly-used graded 
activity. EXP is a method in which patients are trained to overcome their fear of pain and thus 
increase their freedom of movement. This is because patients often 
ǤEXP showed a tendency to reduce disability, increase quality adjusted life years and 
decrease costs compared to graded activity. Based on these results, the authors suggest 
implementing EXP for this group of patients seems to be the best decision. 
A paper comparing psychological treatments to other treatment alternatives have been 
mentioned above; Whitehurst [48] discussed above showed physical therapy to be superior to 
psychological intervention. 
Lastly, Andronis [24] systematically reviewed 33 papers on non-surgical treatment 
alternatives, and found the evidence inconsistent. The paper deemed it likely, however, that 
combination of physical and psychological treatments, medical yoga, information and 
education programmes, spinal manipulation and acupuncture cost-effective. 
4.2.4 Pharmacological treatments 
Wielage et al. [69, 70] published two studies, both based on Markov models of the use of 
duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, compared to non-
steroidal anti-inflammatory drugs. The models incorporated official guidelines, meta-analyses 
of treatment effect on LBP and probabilities of adverse events and found that duloxetine was 
cost-effective.   
Haas [71] conducted a systematic review of these and found seven studies eligible. The 
authors found the literature of low quality, calling for higher-quality studies, more uniform 
presentation of results, and robust modelling.  
4.2.5 Alternative medicine 
Alternative medicine, also called complimentary medicine, is a contested field within 
medicine and specifically the treatment of low back pain. Whereas medical yoga can be 
regarded as physical therapy or exercise, the main category of alternative therapy that has 
been studied in the context of low back pain is acupuncture. 
Herman et al. [72] studied naturopathic care (acupuncture, relaxation exercises, dietary 
advice and a back care booklet) in a small (n=70) study where warehouse workers were 
randomized to either naturopathic care or standardized physiotherapy education and a back 
care booklet. Witt et al. [73] randomized patients into big groups of 1500 each where half got 
acupuncture plus normal treatment while control group did not receive acupuncture. Kim et 
al. [74] synthesize available evidence and include in a model and find acupuncture in 
conjunction with other therapy to be cost-effective in Korean setting. Thomas [75] and later 
Ratcliffe et al. [76] report results from the same randomized controlled trial that show 
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acupuncture to be tolerable, cheap and effective, together making a short course of the 
treatment to be cost-effective.  
4.3 OTHER NON-SURGICAL 
A range of other studies have been published that go beyond specific treatments. These will 
be described very briefly.  
4.3.1 Exercise and self help 
Henchoz [77] assessed a three-month exercise program after multidisciplinary rehabilitation 
showed little effect compared to control group. Both Aboagye [78] and Chuang [79] found 
the relatively cheap intervention of yoga to show signs of being cost-effective. Bastiaenen 
meanwhile [80] looked at such interventions for pregnant women and came to inconclusive 
results.  
4.3.2 Prevention 
Rogerson et al. [81] investigated early interventions for high-risk acute LBP patients and 
found encouraging results. Meanwhile, Ijzelenberg studied whether back pain prevention was 
cost-effective over a range of occupations and found no support for that [82]. 
4.3.3 Other 
Roelofs [83] inspected whether lumbar supports were effective in preventing work loss in 
patients with history of LBP, and found weak evidence in favour of the supports. Both 
Whynes et al. [84] and Manchikanti et al. [85] found epidural injections to have acceptable 
cost-effectiveness.  
4.3.4 Health care provision and structure 
Given the multi-faceted nature of LBP and how spread out the treatment is, studies on the 
structure of health care provision are of potential value. Apeldoorn et al. [86] shows that a 
classification-based system was not cost-effective. Stratified primary care, however, has 
repeatedly been found to be cost-effective, such as by Hill et al. [87] and two studies by 
Whitehurst et al. [88, 89]. Providing integrated care with a clinical occupational physician 
coordinating the care and communication has also shown promise as compared to care 
according to the current treatment guidelines [90]. 
Wilson [91] compared costs and outcomes depending on specialties of the health care 
professionals, and found costs to vary significantly as well as outcomes. The non-randomized 
nature of the study makes the results difficult to interpret. Lastly, Jensen and colleagues [92] 
studied how clinical guidelines are implemented, and found multifaceted approach to be 
superior to usual implementation strategies.  
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5 MATERIALS AND METHODS 
5.1 BURDEN OF LOW BACK PAIN IN SWEDEN (COMMON FOR PAPERS I 
AND II) 
Papers I and II were both part of the same project. Shared methods are presented first, and 
then each paper’s specific methods are described in turn.  
5.1.1 Ethics approval 
The study was approved by the Stockholm Regional Ethics Vetting Board, decision 
2013/2225-31/5 from 6th February 2014.  
5.1.2 Data 
A research database was assembled from several different data sources as detailed below. The 
study population was based on people living in Västra Götaland region (VGR) in Sweden, 
with a population of 1,6 million or around 15% of Sweden’s population. All use of data was 
in accordance with the Swedish law on personal data, Personuppgiftslagen, 1998:204. The 
data sources are described in turn.  
5.1.2.1 County-council database VEGA 
All health care production in region VGR is reported by health care providers to an 
administration database (VEGA). It contains patient-level data in both inpatient and outpatient 
setting, both to specialist and primary care and both from public and private health care 
providers. 
Administration databases were used to identify patients in the study. Additionally, data was 
used to analyse patient history, disease progression, resource utilization and health outcomes. 
5.1.2.2 Quality-of-care register: Swespine 
The Swedish quality-of-care register for spinal surgery is called Swespine and is maintained 
by the Swedish society of spinal surgeons. Swespine registers patients’ health status before 
operation, details about the operation and collects health status at 1, 2, 5 and 10 years after 
operation. Health status information includes quality-of-life data measured by various 
instruments such as EQ-5D.  
5.1.2.3 Population and activity register (LISA), Statistics Sweden 
Statistics Sweden provided socioeconomic factors variables—such as age, income, level of 
education, civic status and country of birth—on health outcomes and costs. Also, information 
about when and where people move was extracted.  
5.1.2.4 Social Insurance Agency register 
Data was extracted describing use of social insurance on an individual basis, most notably 
absence from work. The database includes ICD codes with reason of absence from work, 
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which gives indications of the relative impact of LBP compared to other causes of absence. 
Only absence from work extending the sick-pay period of 14 days are registered in the 
register as shorter spells are covered by the employer and employee. No central data exists 
for work loss in spells shorter than the sick-pay periods.  
5.1.2.5 Prescription register 
The prescription register, maintained by the National Board of Health and Welfare, includes 
data on a variety of properties, such as dosage, anatomic therapeutic classification (ATC) 
codes and costs. The prescription register started in July 2005 in its current form. 
5.1.2.6 National patient register 
The National Board of Health and Welfare keeps the national patient register, a national 
register with information on all inpatient health care visits as well as all outpatient visits 
where these are not in the primary care sector. Similar data to that in VEGA, but covers larger 
geographical area and is less detailed.  
5.1.2.7 Patient selection 
Patients were included in the study population if the patient visited any health care facility in 
VGR during the period 2000-12 with an LBP-related cause. A LBP related cause was defined 
as all lumbar spinal disorders using the following ICD-10 codes: M40, kyphosis and lordosis; 
M41, scoliosis; M43, other deforming dorsopathies; M46, other inflammatory 
spondylopathies; M47, spondylosis; M48, other spondylopathies; M51, other intervertebral 
disc disorders; M53, other dorsopathies, not elsewhere classified; M54, lumbar pain; M99, 
biomechanical lesions, not elsewhere classified, and Q763, congenital scoliosis due to 
congenital bony malformation. LBP due to tumour and trauma were not included. 
5.1.2.8 Data quality 
These databases are regularly used for research purposes in a variety of disease areas. As 
such we expect each of these databases to be of relatively high quality and the data easily 
identified. For example, on average, 98.6% of all inclusions in National Patient Register are 
entered correctly and the frequency of missing values is very low. The loss of patient 
information in the Swedish Prescribed Drug Register is very low, according to the register 
holder. VEGA is administrative and has high quality. The data in the surgical Swespine 
register are of high quality and have substantial long-term follow-up. Today over 95% of all 
spine departments register surgeries in Swespine, the number of patients registered at the time 
of surgery is about 80%, and 1-year follow-up since 2008 is approximately 75%. All these 
numbers are on a national level, which is unique in an international perspective.  
5.1.2.9 Data linkage 
Linkage between data sources was conducted by Statistics Sweden using social security 
numbers and delivered de-identified. This is illustrated in Figure 4.  
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Figure 4: Illustration of the data assembly process. The process starts with sending patient selection criteria to 
the county council. The county council sends its data with social security numbers to Statistics Sweden. Statistics 
Sweden does three things; a) it extracts data from its own registers for the given SSNs; b) it creates a key table 
with all SSNs and keys and sends to other register holders, and c) it sends its data and the data from the county 
council with SSN replaced with the key. The other register holders send extract their data based on the SSNs but 
also replace the SSNs with the key. Upon arriving to the researchers, the data is anonymized but all sharing the 
same personal key.  
5.1.2.10 Technology 
Data management Data management was conducted using a MySQL server, statistical 
analyses using the software package Stata 14, and the model was programmed in Microsoft 
Excel with Visual Basic for Applications. 
5.1.2.11 Unit costs 
Unit costs for healthcare resources were collected from Västra Götaland’s and other Swedish 
county councils’ regional pricelists where unit cost for a resource item was not available from 
Västra Götaland [93, 94]. This price list is highly detailed and publicly available, and cost 
variation across Sweden is deemed small. 
5.1.3 Prices, currencies and other assumptions 
Costs were inflated to the price level of 2016 using consumer price index from Statistics 
Sweden and presented in Euros (€), converted at the average annual exchange rate for 2016 
of 9.47 Swedish Krona per Euro. 
Our data included all visits to primary and secondary care in the Västra Götaland county, 1.6 
million inhabitants (17% of Sweden’s 9.6 million inhabitants). For calculations for the whole 
Swedish population, the case-mix and demographics were assumed to be the same in Västra 
Götaland as in the rest of Sweden. 
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Productivity loss was valued using the human capital approach [95, 96]. This entails that the 
value to the society of productivity loss is measured as the present value of lost time 
according to the market wage, including payroll tax. This tax in Sweden was of 31.42% in 
2016. Unit prices are presented in Supplementary Appendix to paper II [97]. 
5.2 COST OF LOW BACK PAIN (PAPER I) 
The burden of LBP was estimated using a prevalence-based bottom-up approach. This entails 
multiplying the number of incident cases within a defined period of time with the 
corresponding cost. In this study, burden was calculated for LBP episodes, i.e. time periods of 
consecutive events close in time, all related to LBP. A patient could have more than one LBP 
related episode within the study.  
For the purposes of this study, an LBP episode begins with a healthcare contact or the start of 
a work absence period explicitly related to LBP (identified by ICD-10 codes or by being a 
lumbar spine surgery registered in Swespine). The episode continued until six months has 
elapsed without a LBP related healthcare contact or work absence, or if the patient dies (six 
months are commonly used as sign of symptoms resolving) [98]. The end date of an episode 
was set to the date of the last observed LBP contact or day of work absence. This means that 
the start of an episode is always preceded by the absence of LBP related healthcare resource 
consumption for at least 6 months. This is commonly called a wash-out period.  
Although calculations were made for episodes starting in 2008 and onwards, episodes starting 
in 2011 were the basis for primary results. The year 2012 was not included, although the data 
set extracted covered this year, in order to ensure that episodes with long spells of indirect 
costs were not censored. 
In an additional analysis, all healthcare resource use and work loss, considered LBP related or 
not, were summarised per month during the 24 months before and 24 months after the start of 
the first observed LBP episode. Only patients with follow up data for the 24 months before 
and after episode start were included in this analysis. 
The following healthcare visits occurring during an LBP episode were included in the cost 
calculations: general practitioner (GP), other physicians, nurse, physiotherapist, chiropractic, 
psychologist and other healthcare staff. Outpatient visits and inpatient care counted and 
costed if they had a registered LBP related ICD-10 code. However, some types of healthcare 
contacts had no ICD codes or very poor answer ratios. In these cases, the contact was 
considered to be LBP related if it occurred within an LBP episode. This applied primarily to 
visits to physical therapists, which are rarely assigned a diagnosis, and other outpatient visits 
(e.g. assistant nurse, dietician) and hospitalisations without diagnosis code registered. When 
these visits did have an ICD-code that was not LBP-related, the visits were not included even 
if it fell within an LBP-episode.  
Pharmaceuticals in the analyses were pain medication (ATC codes N02A* and N02B*), 
depression medications (ATC N06*), muscle relaxants (ATC M03*) and anti-inflammatory 
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(ATC M01*), with asterisk signifying that all sub-codes were included. Because the drug 
prescription register does not contain diagnosis codes it is not possible to determine the 
underlying cause for prescribing a drug. All drugs with the above ATC codes prescribed 
within an LBP episode were therefore included in the calculations. It follows that drug 
prescriptions did not impact LBP-episode length, such as by starting an episode or prolonging 
an existing one.  
Indirect costs were measured in terms of losses to paid productivity. Absence from work was 
assumed to be LBP related if it had an explicit LBP related ICD code (as defined above), or if 
it had any other code and the work absence period was on-going or started during an LBP 
episode. Two issues with the data needed resolution. First, since data on the proportion of a 
persons’ working time that was covered by a sick benefit during the initial sick-pay period 
(i.e. the first 14 days paid by employer/employee) were not available, patients were assumed 
to be on full-time sick leave/early retirement during this period. Second, overlap between sick 
leave benefit and early retirement had to be adjusted for.  
Changes in the social security system and other structural changes have major impact on the 
use of social benefits [99]. Therefore, a control group consisting of aggregated data from the 
total Swedish population [100] was included as a reference. 
5.3 ECONOMIC MODEL (PAPER II) 
The aim of the model is to simulate how patients move both between different health states 
and between different parts of the healthcare system and capture costs and quality of life. The 
study took a societal perspective, i.e. included both healthcare resource use (e.g. visits to 
physician and inpatient care) and indirect costs in terms of productivity loss). Health effects 
were measured using QALYs and life years. 
The model is run using first-order Monte Carlo simulation (individual state transition model). 
One reason for choosing an individual level simulation technique instead of Markov cohort 
simulation was due to the large number of states required to accurately depict the treatment 
pathway and to capture how transition probabilities are affected by dynamic patient 
characteristics (see chapter 2.2). Its structure is shown in Figure 5.  
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Figure 5: Model outline Model structure. Patient enters the model at the top, to start in a pathway tree of max 
four cycles, where patient can go between visit to specialist, conservative care, and inpatient care. If patient 
enters surgery, he goes into Markov post-surgical care (MPSC). Otherwise, patient enters Markov non-surgical 
care (MNSC) or dies at any stage in the model. 
A patient starts the model at the time of first clinical presentation—the index point—of the 
LBP condition. This is often a visit to primary care physician. After the index point, a patient 
moves through a decision tree for a maximum of four three-month cycles, totalling at most 12 
months. During this period, the patient has a chance of receiving conservative care (defined 
as all outpatient non-surgical care such as physiotherapy), being referred to an orthopaedic or 
neurosurgical specialist, having spine surgery, or being hospitalized due to the LBP-condition 
without having surgery. The clinical pathways included in this model were based on the 
opinion of Swedish physicians, but also by tracking and analysing the observed resource use 
in the registry data.  
If no surgery has been performed during the first 12 months after the index point, the patient 
moves into the Markov Non-Surgical Care (MNSC) sub-model. Patients can enter MNSC in 
any of the following four states; symptoms resolved, sick leave, conservative care, and 
inpatient care. Inpatient care includes surgical treatments not captured within 12 months after 
the index point. 
Lumbar spine surgery was the only orthopaedic treatment included in this analysis. Patients 
who have undergone surgery within the first 12 months move into the Markov Post-Surgical 
Care (MPSC) sub-model. In MPSC, patients have probabilities to go to re-operation, surgical 
complication, or post-surgical recovery, and later into conservative care, sick leave, and 
symptoms resolved. If a patient dies while in MNSC or MPSC, she moves into the absorbing 
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death state. A separate Markov model for death (MD) was included for completeness to 
capture all deaths within the decision tree. The MD model includes only a death state. 
Rulebooks were written for how to assign a patient to a given state in the decision tree. The 
rulebooks both had a set of patient characteristics determining to which state a patient should 
be sent. Also, it has a strict hierarchy so that if a patient fulfils conditions for two states in the 
same cycle, the patient was assigned the state higher in the hierarchy. For details, see [97] and 
its supplementary material.  
The probabilities of moving between health states in each cycle were mainly derived from 
own calculations based on the underlying research database. For the state symptoms resolved, 
mortality was assumed equal to that of the age- and gender-matched general population, 
based on publicly available data from Statistics Sweden.  
QoL estimates for all various health states in the model were not available in the research 
database, except for patients having surgery. QoL data for non-operated patients was derived 
from Burström et al. [101], who estimated EQ-5D index values in the general Swedish 
population and by diseases such as diabetes or depression.  
The aim of the simulation was to follow patients from first presentation of symptoms. 
Therefore, patients were only included if the initial visit was in primary care, and if it was the 
first visit for LBP in 2 years preceding the index-point. 
To analyse the impact of the patient’s characteristics, 11 categorical covariates were used: 
female (yes/no), age, comorbidity, diagnosis group (disc herniation, spondylolisthesis, 
degenerative disc disease, spinal stenosis, lumbar pain, other), income, born in Sweden 
(yes/no), and education level (1–7, where 7 is the highest level). Comorbidity was estimated 
by calculating the Elixhauser comorbidity index [102].  
In the simulation, age was time-dependent, while the other covariates were defined at the end 
of the decision tree and beginning of Markov microsimulation. For the estimation of 
transition probabilities, effects of covariates were taken into account by adjusting the scale 
parameter using the coefficients estimated in the Weibull regression. For costs and QoL, 
ordinary least square regressions were used. 
To control for costs that would have been present even if a patient would not have LBP, the 
model included control groups on costs. This was based on literature. For outpatient visits 
and inpatient care a control group was derived from aggregated data available in the literature 
[9]. These aggregated data were indexed to 2016 price level using the latest published 
consumer price index from Statistics Sweden. The control group for the use of 
pharmaceuticals was derived from a publicly available report of the National Board of Health 
and Welfare [103]. For indirect costs, a control group was derived from the general 
population using official data on sick leave and early retirement from the Social Security 
Agency. The average control costs were deducted for each cycle and patient in the model 
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simulation and was assumed to be the same for all cycles. Productivity control cost was 
deducted for as long as the patient was of working age. 
QALYs lost due to LBP was calculated as the difference in QALYs, assuming that QoL is 
equal to the age- and gender-matched population of the estimated QALYs using the QoL data 
described above. Estimates of QoL in the Swedish general population were collected from 
literature [101]. 
Intangible costs are sometimes considered in studies in the field of health economics, in the 
context of quantifying the health benefit of certain medical treatment or the strain a disease 
causes on the quality-of-life of those affected. Several approaches exist to calculate the 
intangible cost of lost QALYs, including valuing a QALY lost compared with the general 
population using an assumed WTP threshold [16]. Calculating the intangible cost of a lost 
QALY thus requires an assumption on the value of life, as no standardized value exists for 
the monetary value of a QALY. The WTP for a QALY differs among other things on disease 
severity, where the society is willing to pay more for patients facing serious conditions. The 
WTP of a QALY derived from decisions made by the Swedish Dental and Pharmaceutical 
Benefits Agency (TLV) for outpatient drugs was in the interval €79–€135,600 during 2005–
2011 [104]. For the base case calculations, an estimate of €70,000 was used as the valuation 
of a QALY, with lower and higher values used in sensitivity analysis. 
The total societal burden was calculated as the sum of direct costs (outpatient visits, inpatient 
care, and pharmaceuticals), indirect costs (productivity loss), and the intangible value of lost 
QALYs. 
5.4 COST-EFFECTIVENESS OF TOTAL DISC REPLACEMENT (PAPER III) 
In this randomized controlled trial (RCT), 173 patients were randomized to receive either 
total disc replacement (TDR) or multidisciplinary rehabilitation (MDR). Inclusion criteria 
were, among others, LBP with duration of more than one year and degenerative changes in 
lumbosacral intervertebral discs. Data were recorded on follow-up consultations at baseline, 
at 6 weeks, and at 3, 6, 12, and 24 months after treatment. For further details on the patient 
inclusion criteria and methods, see the clinical counterpart to this paper [105]. 
Patients with TDR received disc prosthesis, in the lumbar spine in one or two lower vertebral 
levels. Patients in the MDR group attended treatment groups based on a model described by 
Brox et al. [106]. The program, in outpatient setting combining exercises and cognitive 
behavioural therapy (CBT), was directed by a team of physiotherapists and specialists in 
physical medicine and rehabilitation. It lasted for approximately 60 hours during 3–5 weeks. 
Resource use was collected and valued, using a societal perspective. Cost included the index 
treatment, other hospital care, primary care, patients’ private costs, and costs due to loss of 
production both for the patient and their relatives. Actual costs were assigned to patients 
regardless of their randomized group, so patients who were randomized to receive MDR but 
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crossed over and underwent operation after having had MDR were assigned costs for both 
treatments. 
For TDR, the resource use multiplied by unit costs, and incorporating spare capacity when 
appropriate, summarized the cost for each index treatment. Cost components included the 
prosthesis, operation room time, wake-up services, postoperative stay in hospital, and 
postoperative radiograph. 
For MDR, a top-down approach was needed. The total cost of a spine clinic was estimated, 
and then how much of the clinic's costs were associated with MDR was determined. A 
consequence of this approach is that the costs are the same for all patients. Spare capacity was 
included. A premium of 12% was added to common costs based on data from previous 
estimates of the cost weights for the Norwegian DRG system. Planned and unplanned 
readmissions, including outpatient visits and reoperations, were registered in electronic 
patient administrative systems. Patients who underwent surgery received one mandatory 
consultation with a radiograph 6 weeks after surgery. Patients in the MDR group were 
offered 4 follow-up consultations at 6 weeks and at 3, 6, and 12 months, and costs were 
assigned if accepted. 
Unplanned visits to general practitioners, physiotherapists, or other practitioners in the public 
health service were recorded in a cost diary kept by the patient [107], as well as the use of 
medication (both prescribed and over the counter), contact with practitioners outside the 
public health service, and other costs. Costs for relatives were included when possible.  
Productivity loss is normally a major part of the costs. The human capital approach was used 
to estimate the costs related to days each patient spent out of work due to low back pain. 
Costs related to production losses were calculated as the number of days out of work 
multiplied by the average wage. These were adjusted for part-time sick leave as appropriate. 
Income before taxes was used for patients and after taxes for relatives when calculating costs 
related to work loss as instructed by the Norwegian Medicines Agency [108].  
To measure treatment effects, the EQ-5D was used in the main analysis and SF-6D for 
comparison [15]. Both costs and effects were measured at baseline, at 6 weeks, and at 3, 6, 
12, and 24 months after treatment, thus enabling us to calculate quality-adjusted life years. 
To derive a confidence interval (CI) for the incremental cost-effectiveness ratio, 10,000 
nonparametric bootstraps were simulated. These were plotted in a cost-effectiveness plane to 
illustrate the uncertainty in the ICER. Also, a cost-effectiveness acceptability curve (CEAC) 
was graphed. The CEAC shows how likely a treatment is considered cost-effective given 
different levels of willingness to pay (WTP) for a gain of one QALY. As a baseline, the value 
of NOK 500,000 or €74,600 was used [109]. The intention-to-treat (ITT) method was used, 
and per-protocol analysis (PP) was presented in the sensitivity analysis. 
Missing data were handled by multiple imputations, imputing 5 data sets as commonly 
recommended [110–112]. Student t tests and corresponding 95% CIs were used to analyse 
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differences in cost and utility. Two-sided P-values < 0.05 were regarded as significant. Given 
the short follow-up period, neither treatment effects nor costs were discounted.  
Sensitivity was tested by a) applying different utility measures (EQ-5D and SF-6D) (see for 
example [113]), b) using PP instead of ITT, c) not applying the method of multiple 
imputations, d) applying different estimates for the loss of production, and e) excluding the 
cost of care provided by relatives from calculations. 
5.5 COST-EFFECTIVENESS OF FUSION IN DECOMPRESSION SURGERY 
(PAPER IV) 
We conducted a multicentre, open-label trial in which patients who had lumbar spinal 
stenosis, with or without degenerative spondylolisthesis (DS), were randomly assigned, in a 
1:1 ratio, to undergo either decompression surgery plus fusion surgery (D+F) or 
decompression surgery alone (D). Patients between 50 and 80 years of age with lumbar spinal 
stenosis were recruited, subject to further technical inclusion criteria. 
Simple randomization was performed with the use of a web-based system that enabled 
computer-generated random treatment assignment. Randomization was stratified according to 
the presence or absence of DS. 
Outcomes of this trial were measured with the use of patient-reported data obtained from 
validated questionnaires. Patients were included in the National Swedish Register for Spine 
Surgery (Swespine) database. Swespine collected data before surgery and 2 and 5 years after 
surgery, with periodic reminders to patients when necessary. 
The primary outcome was the score on the Oswestry Disability Index (ODI), a standard for 
measuring degree of disability and estimating quality of life in persons with low back pain. 
EQ-5D was among secondary outcomes collected.  
Additional data for the health economic evaluation were collected by means of special 
questionnaires that were unrelated to the Swespine. The questionnaires were sent before 
surgery and 6 months, 1 year, and 2 years after surgery. Data on direct operation costs were 
obtained from one clinic, Stockholm Spine Center, and used as a proxy for all participating 
clinics. Data on direct and indirect patient costs included the number of visits to health care 
personnel, use of sick leave, participation in the work force, use of pharmaceutical agents, 
length of hospitalizations, personal out-of-pocket expenses, and number of days that family 
members assisted the patient. In accordance with the trial protocol, data on patient costs were 
not collected after 2 years. 
Differences between the two treatment groups were analysed with the use of Student’s t-test 
using per protocol analysis. In addition, we calculated relative risks and 95% confidence 
intervals by comparing outcomes in the two groups. The analysis was performed both with 
and without stratification according to the presence or absence of preoperative DS. Less than 
2% of patients had missing outcome data for each of the variables. 
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As in paper III, we used multiple imputation to create five estimates of missing data in the 
health economic evaluation, including values for age, sex, and scores on the visual-analogue 
scales for back pain and leg pain, the ODI, and the EQ-5D. Values for the health economic 
evaluation were imputed for 30% of patients at the 6-month follow-up, 33% at the 1-year 
follow-up, and 14% at the 2-year follow-up. Calculations of standard deviation and error 
were adjusted to account for the increased size of the data set. 
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6 RESULTS 
6.1 COST OF LOW BACK PAIN (PAPER I) 
In order to assess the economic burden of LBP, all related episodes were identified over a 
four-year period. These made up a total of 167,460 LBP episodes in 134,309 individuals. The 
mean age at episode start was 52 years and 59% were women. The mean total cost for an 
LBP episode was estimated at €2,758. Of total cost, 66% was related to indirect costs (sick 
leave and early retirement). The largest healthcare cost category was visits to physician, 
accounting for 10% of total costs. The smallest cost category was other outpatient visits, i.e. 
visits other than to physician and physiotherapist, which accounted for 1% of the total costs. 
The distribution of costs was highly skewed to the left, indicating that most of costs emerged 
from a minority of the patients. This is manifested in the fact that the median costs are 
markedly lower than the mean.  
Figure 6 presents direct, indirect and total costs per month for 24 months prior and 24 months 
after start of the first observed LBP episode. These numbers include all healthcare resource 
use and work loss whether LBP-related or not. The figure also shows the indirect costs of the 
general population. Costs followed the LBP episode start, with a marked short-term increase 
of costs at the first month after episode start. In the second month after episode start, cost 
levels were noticeably lower compared to the first month. Following the second month, costs 
continued to gradually decrease. At the end of the two-year period, costs had plateaued at a 
higher level than prior to episode start.  
Indirect costs decreased during the years leading up to episode start, mirroring the trend in the 
general population. Changes in the social security system (e.g. the so-called rehabilitation 
chain implemented in 2008) and/or structural changes in the Swedish economy have affected 
the use of sick leave benefits.  
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Figure 6: Mean indirect, direct and total cost per patient and month during 24 months before and 24 months 
after the start of the first LBP episode. The dotted line shows the indirect cost per month in the total Swedish 
population. Includes both LBP related and non-LBP related costs. Shaded areas show 95% confidence intervals 
of the means. 
If the LBP population in VGR in terms of incidence and demographic composition is 
representative for the whole of Sweden, the number of LBP episodes that started in 2011 in 
Sweden was calculated at 293,000. Using this, the societal cost amounts to €739 million, or 
€78 per capita (Table 3). 65% of the total cost could be related to work absence. 
Table 3: Mean national cost (million €) of LBP episodes started in 2011 in Sweden. 
Category Million EUR (€ million) Per capita (€) 
Pharmaceuticals 11 1 
LBP surgery 72 8 
Non-surgical related inpatient care 126 13 
Medical visits 95 10 
Physical therapy 25 3 
Direct costs 258 27 
   
Work absence - sick leave 330 35 
Work absence - early retirement 151 16 
Indirect costs 481 51 
Total costs 739 78 
The data is presented graphically below 
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Figure 7: Breakdown of costs, million euros (same data as in Table 3. 
6.2 ECONOMIC MODEL (PAPER II) 
In total, 154,209 patients were identified in the registry data and included for analysis. Most 
patients (57%) were women, born in Sweden (74%), and the mean age at clinical presentation 
was 50 years. The mean number of comorbidities according to Elixhauser index was 0.7. 
Within 3 months after clinical presentation, 93% consume conservative care. An additional 
6% visit specialists, potentially for surgical evaluation. Twelve months after clinical 
presentation, 90.2% have seen their symptoms resolved, 8.8% have received conservative 
care, 0.5% have undergone surgery or received post-surgical care, and 0.3% have died. This 
is illustrated in Figure 8. Other health states have a low proportion of patients. 
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Mean lifetime costs are, on average, €47,452, as presented Table 4. Pharmaceuticals are the 
smallest single cost category, with 9% of the total costs; inpatient visits constitute 20% of the 
costs, outpatient visits 14%, and indirect costs 57%. 
Table 4: Average discounted cost averaged over the whole patient population.  
Costs Mean Percent of total  
Pharmaceuticals 4,431 9,3% 
Inpatient visits 9,311 19,6% 
Outpatient visits 6,616 13,9% 
Indirect costs 27,095 57,1% 
Total costs  47,452 100% 
 
Quality-of-life Mean QALYs per patient accrued from the point of clinical presentation were 
estimated at 14.0, and the number of life years at 18.0 per patient, as shown in Table 5. The 
burden of LBP in terms of lost QALYs over the lifetime of the patient as compared with the 
age and gender matched Swedish population was estimated at 2.7 per patient.  
The total lifetime cost of all patients coming to clinical presentation in one year in Sweden 
was estimated at €8.8bn. QALYs lost in the same population were estimated at 505,407. 
Table 5: Mean QALYs & life years in the model 
QALYs accrued from clinical presentation 13.97 
QALYs lost 2.7 
 
Valuing this at €70,000 per QALY yields a burden of lost QALYs of €35.3bn. The total 
lifetime costs added together with the intangible cost of lost QALYs yields a total societal 
burden in Sweden of €44.1bn in patients coming to clinical presentation in 1 year. 
6.3 COST-EFFECTIVENESS OF TOTAL DISC (PAPER III) 
Full cost data were provided for 84% of the patients (144 of 173). Baseline characteristics 
were similar between groups, presented in detail in the clinical paper [105]. In all, 13% of 
resource use data during follow-up and 8.3% of utility scores were missing between baseline 
and 24 months. Five patients crossed over from MDR and underwent TDR. Nine patients 
randomized to surgery decided not to undergo surgery. Five patients in the TDR group 
underwent re-operation. 
A significant difference in EQ-5D utilities in favour of TDR was found at all follow-ups 
except at 6 weeks. After 2 years, the mean total improvement in QALYs (standard deviation) 
was 1.29 (0.53) in the TDR group and 0.95 (0.52) in the MDR group, a significant difference 
of 0.34 QALY (95% CI, 0.18–0.50). This is shown in Figure 9. 
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Figure 9: EQ-5D at baseline and follow-ups. Utilities (mean ± 2SE) at time to follow-up derived from EQ-5D 
scoring. Significant difference in favour of TDR was found at all times of follow-up, except at 6 weeks 
(independent 2-sided t-test). 
The mean cost of the index operations was estimated at €10,846 for TDR and €5977 per 
patient with MDR.  
For other cost categories, costs were somewhat different but not the difference was not 
statistically significant. This applies to the follow-up costs (cost of visits to general 
practitioners, physical therapists, and other health care professionals, as well as medication 
use). The same goes for production loss which entailed both personal costs and the work loss 
of relatives.  
The total costs included index treatment and costs during the 2-year follow-up. The total cost 
was €87,622 (58,351) and €74,116 (58,237) in the TDR and MDR groups, respectively. The 
difference of €13,505 was not significant (P = 0.14). This is detailed in Table 6. 
Table 6: Summary of initial treatment and follow-up costs and effect after 2 years follow-up. 
  TDR MDR Mean difference CI p-value 
  Mean SD Mean SD 
   
QALY EQ-5D 1.29 0.53 0.95 0.52 0.34 (0.18 to 0.5) <0.001 
QALY SF-56D 1.33 0.21 1.22 0.18 0.11 (0.05 to 0.17) 0.001 
Index treatment (€) 10,846 1,846 5,977 1,229 4,869 (4,396 to 5,340) <0.001 
Follow-up cost (€) 8,381 10,580 6,609 12,474 1,772 (-1,712 to 5,251) 0.35 
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Loss of production (€) 68,395 54,227 61,528 54,633 6,865 (-9,518 to 23,250) 0.43 
Total cost (€) 87,622 58,351 74,116 58,237 13,506 (-4,440 to 31,452) 0.14 
Using EQ-5D as the measure of quality of life, the mean ICER in the TDR group was 
€39,748/ QALY (95% CI €15,990 to €65,645). We calculated 10,000 bootstrap estimates of 
the ICER, of which 2000 were plotted in the cost-effectiveness plane, illustrating the 
uncertainty of the ICER estimates (Figure 10 ). 
 
Figure 10: Cost-effectiveness plane. Plot of 2,000 bootstrap replications of ICER in a cost–effect plane. For 
calculations, 10,000 replications were made but these are reduced here for illustrative purposes. The plot shows 
that on average, little cost difference seems to be between TDR and MDR, while TDR yields higher QALY 
increase. The black line is the willingness-to-pay for given QALY gain. Dots falling below that line and the 
horizontal red one are cost-effective; dots falling below the horizontal red line are cost-saving. 
If decision makers and relevant stakeholders are willing to pay €74,600 (NOK 500,000) for 
one QALY [109], the chance of TDR being cost-effective from a societal perspective was 
approximately 90% using EQ-5D. This is illustrated in the cost-effectiveness acceptability 
curve in Figure 11. When using a willingness-to-pay limit of three times the gross domestic 
product per capita ($233,000 in 2011 in Norway) as recommended by the World Health 
Organization, TDR was cost-effective irrespective of utility measure used Figure 11). 
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Figure 11: Cost-effectiveness acceptability curve. The vertical line shows a commonly used thresholds for 
maximum willingness to pay (WTP) in Norwegian setting. The curve represents the probability that the cost-
effectiveness of TDR is lower than the corresponding WTP. 
6.3.1 Sensitivity analyses  
Several sensitivity analyses were done to gauge the results’ response to differences in 
assumptions. These are presented in Table 7.  
All analyses were performed using both EQ-5D and SF-6D. Using SF-6D with other base-
case assumptions, the improvement in the TDR group above MDR was 0.11 QALY (95% CI, 
0.05–0.17), somewhat less than the gain of 0.34 QALY (95% CI, 0.18–0.50) using EQ-5D 
was used. The ICER in the TDR group was €128,328/QALY (95% CI €51,329 to €219,907), 
and the chance of TDR being cost-effective from a societal perspective was approximately 
40%, that is not cost-effective (Figure 11). 
Using per-protocol analysis instead of ITT analysis indicated that TDR was not cost-
effective, irrespective of the use of EQ-5D or SF-6D. 
Multiple imputation is the method of inserting a distribution of values into missing fields. 
This is done to avoid excluding patients with a few missing values and to avoid bias. Five 
data sets were created where missing values were replaced with different imputed values, 
reflecting the uncertainty around the missing value. When these methods were not used, a 
considerable number of observations were lost. ICER rose, making TDR not cost-effective. 
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As productivity losses by patients and their relatives constituted a high cost component, we 
arbitrarily raised and lowered the estimated cost per day by 30%. This only had a moderate 
effect on cost-effectiveness and did not alter the conclusions. 
Similarly, days spent by relatives were excluded to see how this changed the results. As 
patients undergoing surgery required more care by their relatives, excluding these costs 
decreased the ICER and thus increased the likelihood of TDR being cost-effective. 
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6.4 COST-EFFECTIVENESS OF FUSION IN DECOMPRESSION SURGERY 
(PAPER IV) 
From October 2006 through June 2012, a total of 247 patients from seven Swedish hospitals 
were enrolled in the trial. No significant differences between the two treatment groups in any 
of the preoperative variables, including general health. A total of 123 patients were assigned 
to the fusion group, and 10 of those patients did not receive the assigned treatment; 124 
patients were assigned to the decompression-alone group, and 4 of those patients did not 
receive the assigned treatment. Therefore, 113 patients underwent decompression surgery 
plus fusion surgery and 120 underwent decompression surgery alone. Five patients were lost 
to follow-up. Therefore, the per-protocol analysis included 228 patients (111 in the fusion 
group and 117 in the decompression-alone group)  
No significant difference between the two treatment groups in the primary outcome; the mean 
score on the ODI at 2 years was 27 in the fusion group and 24 in the decompression alone 
group (P = 0.24).  
This result—a lack of difference between groups—was evident across variables and group 
specifications, the 6-minute walking test being an example of the former and pre-existing 
degenerative spondylolisthesis of the latter. Also, ITT analysis instead of PP showed no 
difference between groups.  
All but one patient consented to participate in the health economic evaluation, with data on 
resource use at 2 years available for 213 patients (92%). EQ-5D values at baseline were 0,37 
for D and 0,39 for D+F. After the operations, QoL jumped to 0,66 and stayed there at the 2-
year follow-up. At no point were QoL statistically different. This is shown in Figure 12. 
Similarly, ODI was not different between groups at any time [114].  
 
Figure 12: Quality of life (mean ± 2SE) at baseline and follow-ups. Difference between groups was not 
statistically significant at any point. See data in Table 8. 
Indeed, among the 153 patients who were enrolled early enough in the trial to have 
potentially completed 5 years of follow-up, 7 had died, 1 had had a major stroke, and 1 had 
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severe dementia; the remaining 144 patients were eligible for the 5-year follow-up 
assessment. Of those patients, 138 (96%) provided information on outcomes. Again, there 
were no significant differences between the fusion group and the decompression-alone group 
in any of the seven patient-reported outcome measures—including EQ-5D—and the results 
were similar among patients with and those without spondylolisthesis (see supplementary 
material to [114]).  
Table 8: EQ-5D at baseline and follow-ups. Same data as in Figure 12. 
 
Decompression Decompression+fusion  
EQ-5D SD SE N EQ-5D SD SE N 
Baseline 0,37 0,30 0,05 119 0,39 0,31 0,06 113 
1 year 0,66 0,30 0,06 119 0,66 0,28 0,05 113 
2 years 0,66 0,30 0,06 119 0,63 0,31 0,06 113 
5 years 0,66 0,29 0,07 73 0,61 0,30 0,07 65 
Resource use is shown in Table 9. The mean direct costs of each procedure (mainly hospital 
costs, including surgery) were $6,800 higher in the D+F group, because of the additional 
operating time, extended hospitalization, and cost of the implant. However, indirect costs 
were similar in the two treatment groups.  
Analyses performed with stratification according to the presence or absence of degenerative 
spondylolisthesis at baseline resulted in outcomes that were similar to the outcomes in the 
overall analysis.  
Table 9: Resource use 
Item D D+F Difference 
Perioperative 
Length of stay (days) 4.06 (0.56) 7.34 (0.79) 3.28, p<0.001 
Operation cost (SEK)* 44,884 101,332 56,448  
Follow-up 
Number of visits to 
doctors (SE) 
1.73 (0.46) 1.29 (0.31) -0.44, p=0.49 
Number of visits to other 
health care professionals 
(SE) 
21.6 (4.1) 13.0 (3.0) -8.86, p=0.13 
Total days on benefits of 
any kind (SE) 
40.7 (10,9) 61.4 (16,4) 23.7, p=0.35 
Still using drugs at 24 
months (SE) 
33.6% (4.3%) 37.2% (4.5%) -3.6%, p=0.57 
*Calculated from hospital accounting system. No measure of distribution available. 
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7 DISCUSSION 
7.1 PAPER-SPECIFIC DISCUSSION 
7.1.1 Burden of Low Back Pain, including Lumbar Disc Herniation and 
Lumbar Spinal Stenosis (common for papers I and II) 
Using a representative Swedish region constituting 17% of the total population in the country, 
an average LBP episode was estimated at 51 days with an average total cost of €2,671. When 
extrapolating the results to the whole of Sweden, the yearly national societal cost of LBP was 
estimated at €739 million in all LBP episodes that started during 2011. The trajectory of total 
costs shows that there is a sharp cost increase at the first month of following the episode start, 
which decreases markedly from the second month after this point. Importantly, costs were not 
entirely restored to pre-episode levels during the two years after the episode start. This 
indicate that LBP has long term consequences on resource use and costs.  
The estimated cost per capita of €78 in 2011 in the current paper I can be compared to 
previous estimates. According to a systematic review of international cost-of-illness studies 
of LBP, the total cost per capita has ranged from €48 to €2,874. Two Swedish studies were 
included in this review, which both estimated considerably higher costs per capita compared 
with our study. Ekman et al. estimated the cost to be €250 per capita in 2016 year prices [9]. 
In this study, direct costs were similar to our estimate while indirect costs were nearly three 
times higher. An explanation might be that the rate of sick leave in the whole Sweden was 
markedly higher around the years 2001–2002, falling from 21 days per individual and year to 
7 in 2010 [99].  
The direct economic cost of LBP per patient was estimated at €47,500, which amounts to 
€8.8bn per year in Sweden. When both indirect costs and intangible costs of QALYs lost 
were added, QALYs, the burden was estimated as €44.1 billion using a WTP of €70,000 per 
QALY, with lost QALYs representing more than half of the total societal burden. 
Most studies on the cost of LBP use a prevalence-based methodology, examining costs 
incurred during a given time period such as 1 year, regardless of the timing of onset of 
disease [31]. In our study, we assessed the lifetime costs in patients from first symptoms, 
which makes it less accurate to compare our estimated costs with other studies. In 2002, 
Ekman et al.[9] estimated the annual cost of LBP per patient at €20,700 in 2002. On a 
national level in Sweden, the total cost has previously been estimated at €1,860m in 2001 and 
€3,346m in persons who were sick-listed for LBP in 1994–1995 [115]. A Swiss study found 
the direct costs of LBP to be €2.5bn and productivity loss at €4.1bn using the human capital 
approach. In the US, the indirect costs for LBP on a national level has been estimated at 
$19,800m [116] and $7,400m [117] in 2002 and 2004, respectively. The health-related 
burden of LBP has been estimated in terms of the DALYs. The Global Burden of Disease 
estimated the global number of lost DALYs in 2010 to 83 million [4].  
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Previous studies have indicated that most of the economic burden of LBP is due to indirect 
costs. Ekman et al. [9] estimated that 85% of the annual cost of LBP were indirect costs and 
Walker et al. [30] 89%. The lower share of indirect costs in our study might be since we used 
a control group of people on sick leave and early retirement from the general population, 
which is more accurate and less likely to overestimate the costs.  
7.1.1.1 Indirect costs 
The use of sick leave/early retirement in the total Swedish population decreased over the 
investigated period. The trajectory of indirect costs before the start of the LBP episodes 
followed this general trend. However, indirect costs remain on a rather stable level after first 
month after episode start, while in the general population, the indirect costs continued to 
decrease. This signals a connection between the cost of LBP on one hand and general 
economic and structural trends in the society on the other. 
7.1.1.2 Modelling approach 
To date, no previous studies have investigated the long-term treatment patterns, costs, and 
QoL of patients with LBP. The estimation of expected costs and health effects of 
interventions at specific time point within a broader care pathway is perhaps the most 
commonly applied economic evaluation to directly inform policy decisions.  
Whole disease modelling, with the aim of assessing the lifetime consequences and/or 
interventions across the entire disease pathway has recently gained more attention. 
Tappenden et al. [118] developed a methodological framework for whole disease modelling. 
While most economic analyses are piecewise, i.e. involve estimation of costs and health 
effects in specific points in a broader treatment pathway, our framework allows multiple 
evaluations of changes in healthcare services. As changes to a specific part of the care 
treatment pathway may have downstream effects, it is important to ensure that all possible 
costs and benefits are incorporated in the analysis. 
A wealth of other modelling approaches were available [20]. One would have been to use 
Markov cohort model. We decided against that approach, mainly because of the need for 
patient history to inform the transition probabilities and outcomes. Another approach, would 
have been discrete event simulation [119]. However, not only are discrete event simulations 
complex to construct and data-hungry, but their complexity and sophistication makes the 
presentation of assumptions and structure very difficult. Thus, transparency and 
reproducibility suffers [120]. 
Modelling requires an assumption of the cycle length which should be decided using the 
timing of events in the progress of the disease in question, study question, and available data, 
among other things. Fixed cycle length affects what type of data needs to be collected and 
forces existing data into unrealistic boxes.  
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The transition probabilities in the model were based on the analysis of Swedish register data 
which provide high-quality data on healthcare resource use.  
7.1.1.3 Intangible costs 
Measuring intangible costs requires an assumption of the value of life, which makes this a 
particularly challenging cost to measure. This value differs between countries and disease 
severity among other things. Thus, there exists several different standards of the value of 
QALY. In this study, we used a WTP threshold of €70,000, which corresponds to the lowest 
interval of the Swedish Dental and Pharmaceutical Benefits Agency WTP for outpatient 
drugs. In reality, the WTP may be much lower for low back pain treatments. We performed a 
sensitivity analysis using WTP thresholds ranging from €20,000–€100,000. This showed the 
linear relationship between the valuation of QALYs and the intangible burden on society. 
Uncertainty around the WTP should not diffuse the main message that in addition to high 
economic burden, the brunt of the effect is in the non-monetary burden. The WTP in the 
model could also easily be altered, depending on different assumptions in different countries. 
7.1.1.4 Limitations  
These studies are not without limitations. Although the data set is unique in its thoroughness 
and detail, some factors could not be assessed. First, the calculations on a national level 
assume that the LBP population in the region of Västra Götaland in terms of incidence and 
demographics is representative for the whole Sweden. Second, the data lacked some variables 
that might be of interest. No direct information was available on diagnostic imaging as these 
are not reported separately in the available data, nor was cost due to durable medical 
equipment available separately.  
We did not have data on sick leaves shorter than 14 days. No data on individual level exists 
on presenteeism (i.e. reduced work capacity when working) or the inability to perform 
household work. Therefore, the indirect cost of work absence may be to some extent 
underestimated.  
Further, out-of-pocket costs for over-the-counter drugs are not included. Another variable of 
interest is paid home help. Fritzell et al. estimated the cost of family support, such as 
housekeeping, for patients eligible for surgical treatment for LBP, reaching estimates between 
€13–16,000 over two years (2016 prices) [107]. Although the patients eligible for surgery is a 
rather small proportion of the total population in our sample, the lack of information in this 
regard is a potential downward bias in our cost estimates.  
Our bottom-up approach relies on coding or context for relating costs to LBP. This might 
underestimate the costs, due to for example lack of coding, costs falling outside the reach of 
our data set, and due to secondary effects of LBP on other health problems.  
Due to the diffuse nature of LBP, and common inaccuracies in initial diagnoses, a very broad 
definition of LBP was used.  
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One possible limitation with data is that we cannot observe if the LBP symptoms truly had 
disappeared. Since a patient was assumed to have its symptoms resolved based on that he or 
she did not visit healthcare or was on sick leave due to LBP symptoms, the proportion of 
patients who have their LBP symptoms resolved may be over-estimated.  
7.1.2 Cost-Effectiveness of total disc replacement for Low Back Pain (Paper 
III) 
This paper compared the outcome of total disc replacement—a surgical procedure—with 
multidisciplinary non-surgical treatment. Both improved quality of life considerably during 
the first two years. Using EQ-5D, the most commonly used instrument in health economic 
evaluations, the chance of TDR being cost-effective was 90% using the threshold of €74,600 
(NOK 500,000) often used in Norway [108, 109]. However, three of the five sensitivity 
analyses performed changed the conclusions: using SF-6D instead of EQ-5D, using per 
protocol analysis instead of ITT analysis, and not using multiple imputations, see Table 7 on 
page 53.  
7.1.2.1 EQ-5D or SF-6D 
Although EQ-5D is the most common assessment used in health economic evaluations, there 
is no general agreement on which instrument is most appropriate. This would be innocuous if 
results were always similar. This is however not the case [15, 113, 121].  
Not only are the two instruments different in the questions and the possible answers, but the 
way these are mapped onto a numerical scale differs. EQ-5D uses time trade-off (TTO) while 
SF-6D standard gamble (SG) [122]. Using SG, people are asked to take a risk while the TTO 
is riskless. Second, while the TTO method assumes a defined period living in perfect health, 
no such time frame is introduced in SG. As a result, TTO—and thus EQ-5D—tends to yield 
lower utilities than SG and SF-6D [123]. This was manifested in the present study, where 
EQ-5D showed a ceiling effect while SF-6D showed a floor effect [15], and unfortunately the 
cost-effectiveness of TDR was dependent on the choice of utility index. 
However, EQ-5D was used as baseline utility measure as it is most widely used in cost-
effectiveness studies. This makes comparisons with other treatment choices easier. In 
addition, more patients had completed the EQ-5D questionnaire resulting in more complete 
data with this index, not surprisingly as one of the main design goals of EQ-5D was 
conciseness to improve completion rates. 
7.1.2.2 Treatment of crossovers and missing values 
The results are different when it comes to how crossovers are analysed. Arguably, patients 
who do not follow their randomized treatment are in one way or another different from the 
rest of their treatment group. Some of these differences can be observed, but unobserved 
differences cannot be ruled out either. For this reason, ITT analysis is considered the gold 
standard in health economic evaluations [23].  
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Moreover, questions in health economics often are about what policy health authorities 
should adopt and which should be rejected. In this sense, the question is not whether a 
surgery works, but whether the decision to operate surgically is a good policy or not, 
regardless of whether the patients all receive the operation or not. This view has parallels in 
studies of self-administered pharmaceuticals, where the interesting question from a health 
economic perspective is whether prescription of drug is cost-effective rather than the 
narrower use of drugs.  
7.1.2.3  Multidisciplinary rehabilitation: what is it? 
The effects of MDR on function and pain are described in the literature as strong to moderate, 
and no serious complications have been described [124, 125]. However, no consensus about a 
standard treatment regime exists, which makes it difficult to compare studies and choose a 
specific treatment. The MDR regimen used in this study has been shown to be acceptable as 
compared to fusion [124, 126]. The MDR procedure used in this study was described in 
articles published in 2003 and 2006 [106, 124]. and is referred to as the Brox regimen. An 
important element is the cognitive intervention. This includes exposing the patients to non-
recommended activities and attempts to give the patient a new understanding of their 
problem. As described in chapter 4.2.3 on page 30, LBP has an important psychological 
element. 
7.1.2.4 Indirect costs 
Although the difference between the two groups was not statistically significant, there was an 
observed difference between the groups. This difference had big impact on the cost-
effectiveness estimates. This is because the indirect costs were far higher than the direct costs. 
The difference in costs derived from the insignificant difference in return to work should thus 
be interpreted with caution. 
7.1.2.5  Limitations 
Looking at Figure 9 on page 49, it is apparent that at the end of the follow-up time, QoL is 
significantly different. It is thus safe to assume that longer follow-up time would show 
decidedly better cost-effectiveness for surgery than the baseline results indicate. A modelled 
analysis based on either data from other sources or longer follow-up within the same study 
would have permitted us to extend the follow- up period beyond 2 years and to include 
estimates of rare events. Also, with a modelling approach, other relevant treatment options 
(either a different kind of nonsurgical treatment or no treatment) could be compared with 
TDR.  
7.1.3 Cost-Effectiveness of fusion in decompression surgery for Lumbar 
Spinal Stenosis (paper IV) 
This RCT revealed no clinical benefit 2 years after surgery of adding fusion surgery to 
decompression surgery. This was the case regardless of analyses methods and across different 
subgroup specifications. Approximately two thirds of the patients involved in the trial had a 
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follow-up longer than 5 years, and the lack of superiority of decompression plus fusion 
persists at 5 years among those patients. The more expensive surgery—with fusion—
constitutes thus waste of health care resources.  
Table 10: Decompression and decompression + fusion. Data from Swespine yearly reports 
 
Decompression +fusion Decompression Fusion of all 
2011 835 1426 37% 
2012 768 2717 22% 
2013 790 2986 21% 
2014 665 3217 17% 
2015 NA NA 12% 
2016 NA NA 9% 
Of all surgeries in 2016 reported into Swespine database, 50% were for spinal stenosis. Of 
these, the vast majority were simple decompression surgeries or 87% and 7% decompression 
with fusion [127]. This was not always the case. In 2011, 37% of decompressions involved 
fusion. However, as the science began to evolve, and results from Swespine analyses started 
to emerge, for example in the 2013 paper of Försth et al. [128], this began to change, and in 
2016, 9% included fusion. This has led to great savings of health care resources.  
7.1.3.1 Robust results 
In contrast to paper III, the results are robust across different assumptions. The results are 
valid only for patients who have spinal stenosis at one or two adjacent lumbar vertebral 
levels, with or without degenerative spondylolisthesis; this is the case for most patients with 
lumbar spinal stenosis and constitutes the most common indication for spine surgery. The 
per-protocol analysis and the modified intention-to-treat analysis (with only five patients who 
received an intervention missing from the analysis) revealed only minor differences between 
groups in overall results. 
7.1.3.2 Similar studies 
Several recent cohort studies have not shown any substantial benefit from the addition of 
fusion surgery to decompression surgery for lumbar spinal stenosis, even in the presence of 
spondylolisthesis [129–131]. A big analysis of the Swespine registry comes to the same 
conclusion [128]. 
However, the results of our trial might at first seem to contrast with the findings of 
Ghogawala et al. [132]. In their trial, the addition of fusion surgery to decompression surgery 
resulted in moderately superior scores on the SF-36 physical-component summary but not on 
the Oswestry disability index. However, the trial by Ghogawala et al. had a higher dropout 
rate and a substantially higher reoperation rate during follow-up in the decompression-alone 
group than in the fusion group (34% vs. 14%). This could have affected the results of the SF-
36 assessment.  
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7.1.3.3 Fusion in addition to decompression is wasteful and potentially harmful 
The addition of fusion surgery to decompression surgery significantly increased direct 
hospital costs, including the costs of surgery and the in-hospital stay, but did not increase 
indirect costs at 2 years. Although economic data at 5 years were not collected, the clinical 
results and in particular the similar rates of reoperation in the two treatment groups indicate 
that the outcomes at 2 years are robust. As compared with decompression plus fusion, the use 
of decompression surgery alone not only is associated with a lower treatment cost per patient 
but also can save resources by releasing surgical capacity because of shorter operating time 
and hospitalization. 
A large analysis of registry data showed that the addition of fusion surgery to decompression 
surgery doubled the risk of severe adverse events and was associated with an absolute risk 
difference that corresponded to a number needed to harm of 30 treated patients [133, 134]. 
Our trial was not powered to analyse differences in complication rates. 
7.2 GENERAL DISCUSSION 
The elusive nature of low back pain (LBP), including lumbar disc herniation (LDH) and 
lumbar spinal stenosis (LSS) is one of the reasons why it is such a stubborn and costly 
disorder. The causes can be numerous. Diagnostics are very difficult. Indeed, many diagnoses 
are symptom-based as opposed to pathophysiological.  
The available treatments are legion, ranging from no treatment, yoga and exercise to complex 
surgical procedures. The treatments’ effectiveness is also often difficult to measure. As 
compared to the pharmaceutical industry where patents protect investments in expensive 
medical studies, the medical device industry has less incentive to study back pain and its 
treatments. In many cases, no treatment has been shown to be the best choice, but this can 
often be problematic for patients who prefer treatment to treat their debilitating pain to 
another round of wait-and-see with pain medication of differing efficacy. Therefore, the 
upwards trend of costs and burden do not show any signs of reversal.  
The results from paper IV, which indicate the overuse of a more expensive and invasive 
treatment option for lumbar spinal stenosis, are a reminder that careful research, even on 
treatments that have been used for decades, has the potential of saving money without 
sacrificing treatment quality. Here, both register data and RCT’s were used to arrive at similar 
conclusions. It is therefore good news that the proportion of fusions in connection with 
decompression, even in the presence of a degenerative slip, a spondylolisthesis, has been 
falling steadily in Sweden in the last decade.  
Following the publication of this paper, multiple commentaries were published. Most were 
favourable to the study, its design and results. For example, in a commentary, Nancy Epstein 
asked: “With this clear message, why are so many spinal surgeons still offering fusions […]? 
Clearly, these fusions increase perioperative risks and complications resulting in longer LOS, 
even without considering the greater surgical/operative costs. How long will it take before 
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this clear message trickles down through the system and benefits the geriatric patients it 
presently hurts?” [135].  
“Finally, when can we look forward to fewer morbidity/mortality conferences filled with 
these patients who are still undergoing unnecessarily extensive fusions resulting in a 
multitude of adverse events?” Epstein asked.  
This thesis combines different methodologies and data sources. Prospective controlled studies 
have their pros and cons vis-à-vis retrospective register studies. Combining these two, for 
example by collecting data with the infrastructure of registries as done here, or by modelling 
where data from different sources are combined into a more complete whole, is an exciting 
way forward to combine the best of both worlds.  
This also points to the more general issue of the value of health economic research. Mapping 
burden, and continually questioning the cost-effectiveness of various interventions is, in and 
of itself, a cost-effective endeavour. In relation with the total expenditure in the health care 
sector and the likelihood that current practices are inefficient, the cost of research is relatively 
low. However, this is not entirely unproblematic. As opposed to research in pharmaceuticals, 
orthopaedic research is impeded by infinite variations of techniques and approaches. Also, 
although such interventions are just as susceptible to the placebo effect, blinding through 
sham studies is problematic. Without careful randomisation and/or sophisticated statistics, 
bias is likely to show up, and confounders will pose a problem. However, using correct 
methods, several studies have reported that results achieved in observational studies are of 
equal significance as those from RCTs (see for example [11, 21, 136]).  
Indeed, the part of the research team behind paper IV previously published a registry-based 
study using Swespine data. The study came to similar conclusions as the one presented here 
[128], stating that at two years, there was no significant difference in patient satisfaction 
between the two treatment groups for any of the outcome measures and that the proportion of 
patients who required subsequent further lumbar surgery was also similar in the two groups. 
The paper concludes that “In this large cohort the addition of fusion to decompression was 
not associated with an improved outcome.” 
 
7.3 FUTURE RESEARCH 
Going through the papers specifically, papers I and II present interesting data set and model 
that could be explored further. Partly, this has already been done, in a paper examining the 
treatment patterns of patients following referral to specialist [137]. 
The model, presented in paper II, can be populated with data from different regions in 
Sweden, or from different countries, making it potentially a valuable tool for decision-making 
in structuring healthcare in regions or countries. Importantly, data from other contexts can be 
supplemented with the existing Swedish data or data from published sources where needed, 
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and still provide valuable insights into the burden and its different aspects in various 
countries. A potential expansion of the model is also to populate it with data from 
randomized controlled trials on the efficacy of different interventions.  
Paper III, which as mentioned in chapter 0 was plagued by distorting horizon effect, should 
be revisited with longer-term data, either from the same population, from different population 
if possible, or as a fall-back option, with assumptions. The last exercise could reveal results 
according to different scenarios and as such be informative in its own albeit limited right.  
Paper IV has huge potential impact and could be followed-up by detailing treatment patterns 
around the world and investigating whether and where low-value treatments are being used 
against current best evidence.  
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8 CONCLUSIONS 
In paper I, we present cost estimates of the burden of low back pain in Sweden. The mean 
cost per LBP episode/patient was estimated at €2,761 and the total economic cost of all 
episodes that started in 2011 was estimated at €739 m (€78 per capita).  
Most patients have a relatively benign course of the disorder, but a significant number 
experiences chronic symptoms. After onset of an LBP episode and different treatments, mean 
costs were not entirely restored to pre-episode levels during the two-year after the episode 
start, i.e. when the patient was first recorded in a health care register. This could be due to a 
continuous degenerative process that in fact has some persisting consequence to the patient, 
or a sign that the social and healthcare systems are not functioning optimally. The study gives 
no direct guidance of how resources should be allocated to improve efficiency but points at 
the importance of the consequences of LBP of different origin, both for the individual 
patients and the society. 
Building on the data collected for paper I, paper II presents a novel economic model of 
lifetime treatment pathway based on both societal costs and quality-of-life in patients 
suffering from LBP of different origin. The large size of the underlying dataset, and the 
sophistication of the model, makes it, according to our knowledge, unique. The model shows 
that most patients with LBP receive conservative care, and a minority consume high-cost 
healthcare interventions like surgery.  
Going into details on a specific treatment option for patients where their LBP is due to 
degenerated discs, the study finds that replacing the disc is potentially cost-effective in a short 
time perspective compared to the multidisciplinary alternative. The result was however not 
unequivocal and merits further research, particularly with longer follow-up.  
Lastly, we find that in patients with lumbar spinal stenosis involving one or two adjacent 
vertebral levels, with or without degenerative spondylolisthesis, decompression with fusion 
did not result in clinical outcomes that were superior to those with decompression surgery 
alone. This indicates that a more invasive and expensive treatment has been used without 
merit for decades. 
LBP of different origins is the most burdensome disease category in many Western societies. 
It is imperative to monitor how and where resources are spent and allocate them where they 
come of most use.  
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Ländryggssmärta har de senaste åren stigit till att ha den tyngsta sjukdomsbördan av alla 
sjukdomskategorier, enligt WHO:s mätningar. Detta är på grund av att ländryggssmärta är 
vanligt förekommande, är långvarig, ofta mycket smärtsam, kan påverka relativt unga 
människor och medför ofta stora kostnader, både inom sjukvårdssystemet och genom sin 
effekt på deltagande på arbetsmarknaden.  
Ländryggssmärta är ett brett begrepp. Det innefattar oftast inte bara smärta i ländryggen, utan 
även i andra delar av kroppen, som till exempel i ben som kan bero på trängsel i 
ryggmärgskanalen, vilken i sin tur kan bero på ett diskbråck eller en spinal stenos 
(förträngning av ryggmärgskanalen). Smärtan är inte sällan muskulär, och kan bero på 
felaktig hållning och därav felaktig belastning på olika leder eller muskler. Diagnostik är ofta 
mycket svår. Olika behandlingsstrategier finns i stor mängd, och har varierande effekt.  
Denna avhandling undersöker hälsoekonomiska aspekter av ländryggssmärta med eller utan 
utstrålning i benen, och består av fyra delarbeten. De två första använder sig av mycket stor 
databas som sammanställdes från olika nationella databaser och innehåller alla besök i Västra 
Götalandsregionen som inkluderar ryggsmärta under åren 2008–12. I den sammanställda 
databasen har vi även information om besök i sluten och öppen vård, sjukskrivningar, 
läkemedelsförskrivningar, kirurgiska operationer med mera.  
I delarbete I analyserar vi den totala kostnaden i Sverige av ländryggsmärta kopplade till 
olika diagnoser och med eller utan bensmärta. Vi definierar en ryggepisod, som första 
dokumenterade besöket till en terapeut där ryggdiagnos anges som första ICD-kodade 
diagnos, och två år innan ett besök till ortopedspecialist, och sedan vidare till två år efter detta 
specialistbesök. Alla sjukvårdsbesök och kostnader ingår under denna fyra-års-period ingår. 
En episod anses avslutad om vi inte har hittat någon användning av sjukvårdens resurser på 6 
månader. Vi kommer fram till att genomsnittsepisoden kostar €2 761 och att alla episoder 
som började år 2011 kostade €739 miljoner, eller €78 per capita.  
De flesta patienterna förbättras spontant, utan större samhällskostnader. Dock fick en 
signifikant andel med kroniska besvär som leder till avsevärda kostnader. Snittkostnaden 
faller därför inte helt ner till det den nivå den var två år innan episoden startade, vilket kan ses 
som ett tecken på att vi studerar en degenerativ åkomma. Studien ger inte direkta svar på hur 
behandling ska optimalt vara, men visar mönster och vikten av ländryggssmärta både för den 
enskilda patienten och samhället i stort.  
Med hjälp av ovan beskrivna databas, beskriver delarbete II en ny hälsoekonomisk modell av 
livtidsbehandling av ländryggsmärta. Denna behandling är baserad på både kostnader och 
livskvalitetsmått. Storleken på databasen och detaljerna i modellen gör den unik i litteraturen. 
Modellen visar att de flesta patienterna får konservativ behandling och en minoritet 
konsumerar dyra ingrepp och behandlingar såsom kirurgi.  
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Delarbete III går mer i detalj. Där undersöks, i en randomiserad kontrollerad studie, om ett 
kirurgisk ingrepp för kronisk ländryggsmärta var kostnadseffektivt jämfört med icke-
kirurgisk multidisciplinär behandling. Detta kunde inte bevisas.  
I delarbete IV presenteras resultat från en annan randomiserad studie där patienter med 
förträngning i ryggradskanalen behandlades med antingen endast dekompression, ett 
kirurgiskt ingrepp där delar av kotbågen och benpålagringar tas bort, eller i kombination med 
en steloperation (fusion). Hälften av patienterna stelopererades i samband med 
dekompressionen, medan hälften fick endast en dekompression, som också kallas för 
nervfriläggning. Den förstnämnda kirurgin tar längre tid och är dyrare. Resultatet visar att 
tillägg av fusion inte förbättrade resultaten på vilket sätt det mättes. Detta betyder att denna 
dyrare version, dekompression plus fusion vid lumbal spinal stenos, har utförts utan att det 
medför något värde för patienterna eller samhället. 
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